REVIEW

Podocytes [version 1; peer review: 2 approved]

Jochen Reiser , Mehmet M. Altintas

Department of Medicine, Rush University Medical Center, Chicago, IL, USA

V1 First published: 28 Jan 2016, 5(F1000 Faculty Rev):114
<https://doi.org/10.12688/f1000research.7255.1>
 Latest published: 28 Jan 2016, 5(F1000 Faculty Rev):114
<https://doi.org/10.12688/f1000research.7255.1>

Abstract

Podocytes are highly specialized cells of the kidney glomerulus that wrap around capillaries and that neighbor cells of the Bowman's capsule. When it comes to glomerular filtration, podocytes play an active role in preventing plasma proteins from entering the urinary ultrafiltrate by providing a barrier comprising filtration slits between foot processes, which in aggregate represent a dynamic network of cellular extensions. Foot processes interdigitate with foot processes from adjacent podocytes and form a network of narrow and rather uniform gaps. The fenestrated endothelial cells retain blood cells but permit passage of small solutes and an overlying basement membrane less permeable to macromolecules, in particular to albumin. The cytoskeletal dynamics and structural plasticity of podocytes as well as the signaling between each of these distinct layers are essential for an efficient glomerular filtration and thus for proper renal function. The genetic or acquired impairment of podocytes may lead to foot process effacement (podocyte fusion or retraction), a morphological hallmark of proteinuric renal diseases. Here, we briefly discuss aspects of a contemporary view of podocytes in glomerular filtration, the patterns of structural changes in podocytes associated with common glomerular diseases, and the current state of basic and clinical research.

Keywords

Podocytes , kidney glomerulus , urinary ultrafiltrate , glomerular filtration

Open Peer Review**Approval Status**

	1	2
version 1 28 Jan 2016

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Sumant Chugh**, University of Alabama, Birmingham, USA
2. **Farhad Danesh**, The University of Texas MD Anderson Cancer Center, Houston, USA

Any comments on the article can be found at the end of the article.

Corresponding author: Jochen Reiser (Jochen_Reiser@rush.edu)

Competing interests: Jochen Reiser has pending and issued patents on novel strategies for kidney therapeutics and stands to gain royalties from their commercialization. He is co-founder of TRISAQ (Miami, FL, USA), a biotechnology company in which he has financial interest, including stock. MA declares that he has no competing interests.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2016 Reiser J and Altintas MM. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Reiser J and Altintas MM. **Podocytes [version 1; peer review: 2 approved]** F1000Research 2016, 5(F1000 Faculty Rev):114 <https://doi.org/10.12688/f1000research.7255.1>

First published: 28 Jan 2016, 5(F1000 Faculty Rev):114 <https://doi.org/10.12688/f1000research.7255.1>

Podocytes and glomerular filtration

Podocytes (or visceral epithelial cells) are terminally differentiated cells lining the outer surface of the glomerular capillaries. As a major component of the ultrafiltration apparatus, podocytes have a complex cellular architecture consisting of cell body, major processes that extend outward from their cell body, forming interdigitated foot processes (FPs) that enwrap the glomerular capillaries¹. Major processes are tethered by microtubules and intermediate filaments while FPs contain actin-based cytoskeleton²⁻⁴. Podocyte FPs comprise a functioning slit diaphragm (SD) in between^{5,6}, a meshwork of proteins actively participating in podocyte signaling⁷⁻⁹. In addition, FPs have a thick, negatively charged coat (glycocalyx) facing the urinary space¹⁰; this accounts for negative surface charges throughout the glomerular filtration barrier, which generates an electrostatic repel between the neighboring FPs and helps maintain the unique cytoarchitecture of podocytes by enhancing the physical separation¹¹. Podocytes form the glomerular filtration barrier together with the opposing monolayers of fenestrated endothelium in the vascular space¹² and glomerular basement membrane (GBM) in between^{13,14}. This three-layer filtration barrier serves as a size-selective and charge-dependent molecular sieve facilitating the filtration of cationic molecules, electrolytes, and small and mid-sized solutes but restricting the passage of anionic molecules and macromolecules^{15,16}. It is important to bear in mind that those layers should be arranged with decreasing selectivity, with the SD being the least selective filter; otherwise, retained plasma proteins would routinely accumulate behind the filtration slits of podocytes¹⁷. This elegant structure has to oppose hydrostatic pressure in the glomerular capillary, which is the natural driving force behind macromolecular filtration.

If podocytes are injured, mutated, or lost, the elaborate structure of podocytes is physically altered—a process termed ‘foot process effacement’, which is found in many proteinuric kidney diseases. In some cases, once FPs are effaced (flattened down and fused), the glomerular filtration barrier is no longer intact as evidently indicated by the massive leak of proteins out of the vasculature into the urine, known as proteinuria¹⁸. Proteinuria (also referred to as ‘albuminuria’ or ‘microalbuminuria’) is a clinically important sign of early renal dysfunction. In the following sections, we outline the response of podocytes to various stimuli or injury (or both) to better understand the mechanisms underlying podocyte FP effacement, proteinuria, and glomerular disease progression.

Major causes of podocyte injury

Podocyte function depends on a highly ordered cellular arrangement of filtration compartments and the correct signaling within this microenvironment. Therefore, podocytes are uniquely sensitive to a variety of agents interfering with their actin cytoskeleton, their apical membrane domain (i.e., the negative surface charge), SD complex that regulates podocyte actin reorganization, and GBM structure to which podocytes adhere¹⁹⁻²¹. The mechanisms leading to podocytopathies at the molecular level include genetic events (genetic mutations and deletions) associated with common complex diseases^{22,23}.

The core structural component of podocyte FPs is a highly regulated actin cytoskeletal network, which was represented either by a dense bundle of actin filaments that extends along the length of

FPs or by a relatively short and branched cortical network, which is located at the cell periphery and anchors elements of the SD. The initial response of podocytes to injury is the disruption of these structures and actin dysregulation, where actin and actin-binding proteins accumulate.

In experimental models aiming to study various aspects of cell and molecular biology of podocytes, it has been demonstrated that podocytes are the major targets of various soluble and cellular products, including toxins, reactive oxygen species (ROS), complements, and antibodies, as outlined in [Table 1](#).

A commonly used experimental model to induce glomerular proteinuria is puromycin aminonucleoside (PAN) injection into rats. Upon PAN treatment, podocytes undergo significant alterations ranging from FP effacement and cytoskeletal rearrangement to diminished levels of actin cytoskeleton- and SD-associated proteins²⁴⁻²⁸. Abnormal distribution of SD proteins²⁹ and increasing levels of tight junction proteins^{6,30,31} are also reported. Rats develop proteinuria after 4 or 5 days. The early phase of proteinuria is related to the secretion of hyposialylated angiopoietin-like 4 (ANGPTL4) from podocytes, which binds avidly to the GBM and is sensitive to glucocorticoids³². Later stages may be mediated by direct oxidative mechanisms. Many pharmacological agents, including dexamethasone^{33,34}, fluvastatin³⁵, erythropoietin analog darbepoetin³⁶, mizoribine³⁷, sialic acid³⁸, and nuclear factor kappa B (NF- κ B) inhibitor dehydroxymethylepoxyquinomicin (DHMEQ)³⁹, have been shown to possess the ability to reverse the reorganized stress fiber and cortical actin fiber phenotype observed after PAN treatment.

Similar structural and functional abnormalities are observed in a rat model of adriamycin (ADR)⁴⁰⁻⁴⁴. However, podocyte cytoskeleton returns to almost normal appearance by day 20 in PAN-treated rats, whereas pathological and functional changes progress and proteinuria sustains during a similar period of time in ADR-induced nephropathy. Of note, most mouse strains are not susceptible to either of these reagents except BALB/c and BALB/cJ mice, which develop severe proteinuria and progressive renal failure following ADR administration^{45,46}. Recently, a nuclear DNA repair protein Prkdc (protein kinase, DNA-activated, catalytic peptide) was discovered to participate in the maintenance of the mitochondrial genome and prevent ADR-induced nephropathy⁴⁷. Simvastatin⁴⁸ and thiazolidinedione⁴⁹ also confer renoprotective phenotype in response to ADR.

Other toxins, which act on podocytes and have been used experimentally, include diphtheria toxin (DT)⁵⁰⁻⁵² secreted by *Corynebacterium diphtheria*, which causes acute loss of podocytes in inducible diphtheria toxin receptor (iDTR) mice; uremic toxin indoxyl sulfate⁵³, which decreases the expression of podocyte differentiation and functional marker proteins; and hemolytic uremic Shiga toxin⁵⁴⁻⁵⁶, which mediates the release of inflammatory cytokines and vasoactive mediators while potentially inhibiting protein synthesis.

These models represent irreversible glomerular damage with major (20% and above *in vivo*) podocyte depletion⁵⁰, which leads to progressive renal failure. If podocyte loss is less than this threshold, then podocytes have the capacity to recover the normal structure

Table 1. Agents, molecules, and genes associated with podocyte injury and foot process effacement.

Means of injury	Category	Agent/Molecule/Gene	References
Toxicity	Actin reorganization	Adriamycin	40–49
		Diphtheria toxin	50–52
		Indoxyl sulfate	53
		Puromycin aminonucleoside	6,24–39
		Shigatoxin	54–56
Immunologic	Actin reorganization	Complement proteins	66–70
		Lipopolysaccharides	57–63
		Polyinosinic-polycytidylic acid	65
	Anti-GBM antibodies	Rabbit anti-mouse GBM antiserum	71–74
		Rabbit anti-rat GBM antiserum	75,76
		Sheep anti-rabbit GBM antiserum	77,78
Charge distortion	Podocyte polarity	Poly-L-lysine	85
		Protamine sulfate	30,79–87
		Sialidase	11,88
Signaling pathway activation	Actin reorganization and motility	Angiopoietin-like3 (ANGPTL3)	271
		B7-1 (CD80)	57,272
		Cytosolic cathepsin L (cCATL)	61–64
		Glucose	273–277
		Glutamine	64
		Insulin	227
		Integrin $\beta 3$ (ITGB3)	60,278
		Tumor necrosis factor- α (TNF- α)	279–281
		Transient receptor potential cation channel 5/6 (TRPC5 and TRPC6)	282
		Urokinase-type plasminogen activator receptor (uPAR)	60
	Apoptosis and mitochondrial dysfunction	Albumin	283–285
		Aldosterone	286–288
		Angiopoietin-like 3 (ANGPTL3)	289
		Angiotensin II	290–294
		Fatty acids	295–297
		Glucose	232,294,298
		IGF-binding protein-3 (IGFBP-3)	299
		Oxidized low-density lipoprotein (LDL)	300
		Transforming growth factor- $\beta 1$ (TGF- $\beta 1$)	237,301–304
	Autophagy	Angiotensin II	305
		Glucose	306
	EMT	Endothelin-1 (ET-1)	263
		Integrin-linked kinase (ILK)	212
		Puromycin aminonucleoside	262
		Transforming growth factor- $\beta 1$ (TGF- $\beta 1$)	308
	Proliferative	Negative factor (NEF)	309,310
		Tumor necrosis factor- α (TNF- α)	311
	Proteinuric	Hypo-sialylated angiopoietin-like 4 (ANGPTL4)	32
		Soluble urokinase-type plasminogen activator receptor (suPAR)	278
	Anti-proteinuric	Circulating sialylated angiopoietin-like 4 (ANGPTL4)	312
	Survival	Activated protein C (APC)	313,314
		Bone morphogenetic protein-7 (BMP7)	277,299,315
		Insulin-like growth factor-II (IGF-II)	228
		Vascular endothelial growth factor A (VEGF-A)	316–318
		Vascular endothelial growth factor C (VEGF-C)	318,319

Means of injury	Category	Agent/Molecule/Gene	References
Genetic modification	Actin-regulating proteins and enzymes	aarF domain containing kinase 4 (<i>ADCK4</i>)	99
		α -actinin 4 (<i>ACTN4</i>)	93–96
		Anillin (<i>ANLN</i>)	100
		Apolipoprotein L1 (<i>APOL1</i>)	101
		RhoA-activated Rac1 GTPase-activating protein 24 (<i>ARHGAP24</i>)	102
		Rho guanine nucleotide dissociation inhibitor- α (<i>ARHGDI1A</i>)	103–105
		Claudin-1 (<i>CLDN1</i>)	106
		Chloride intracellular channel 5A (<i>CLIC5A</i>)	107
		Cofilin-1 (<i>CFL1</i>)	108,109
		Dynamin (<i>DYN</i>)	61,97,98
		Ezrin (<i>EZR</i>)	110
		Inverted formin 2 (<i>INF2</i>)	111–114
		Kidney ankyrin repeat-containing protein (<i>KANK1</i> , <i>KANK2</i> , and <i>KANK4</i>)	115
		Neuronal Wiskott-Aldrich syndrome protein (<i>N-WASP</i>)	116
		Class II phosphoinositide 3-kinase C2 α (<i>PI3KC2α</i>)	117
		Phospholipase C ϵ 1 (<i>PLCE1</i>)	118
		Rac1 (<i>RAC1</i>)	119,120
		Rhopilin 1 (<i>RHPN1</i>)	121
		Schwannomin interacting protein 1 (<i>SCHIP1</i>)	122
		Synaptopodin (<i>SYNPO</i>)	90–92
		WT1-interacting protein (<i>WTIP</i>)	123
	Lysosomal protein	Lysosome membrane protein 2 (<i>SCARB2/LIMP2</i>)	190
	Mitochondrial proteins	Coenzyme Q ₂ (<i>COQ2</i>)	191
		Coenzyme Q ₆ (<i>COQ6</i>)	192
		Mpv17 (<i>MPV17</i>)	193
		Mitochondrial tRNA leucine 1 (<i>MTTL1</i>)	194
		Prohibitin ring complex subunit prohibitin-2 (<i>PHB2</i>)	195
	Transcription factors	C-Maf-inducing protein (<i>CMIP</i>)	242,243
		Forkhead box C2 (<i>FOXC2</i>)	244
		Hypoxia-inducible factor 1 α (<i>HIF1A</i>)	245–247
		Krüppel-like factor 6 (<i>KLF6</i>)	248
		LIM homeobox transcription factor 1 β (<i>LMX1B</i>)	249–254
		V-Maf avian musculoaponeurotic fibrosarcoma oncogene homolog B (<i>MAFB</i>)	255,256
		Nuclear factor of activated T cells (<i>NFAT</i>)	257,258
		Paired box gene 2 (<i>PAX2</i>)	259
		Podocyte-expressed 1/Transcription factor 21 (<i>POD1/TCF21</i>)	260
		Peroxisome proliferator-activated receptor- α (<i>PPARA</i>)	261
		Snail family zinc finger 1 (<i>SNAI1</i>)	262,263
		Wilm's tumor 1 (<i>WT-1</i>)	264–268
		Zinc finger E-box-binding homeobox 2 (<i>ZEB2</i>)	269
		Zinc fingers and homeoboxes 1/2/3 (<i>ZHX1</i> , <i>ZHX2</i> , <i>ZHX3</i>)	270
	Apoptosis and survival	Dendrin (<i>DDN</i>)	203
		Survivin (<i>BIRC5</i>)	204
		Vascular endothelial growth factor A (<i>VEGF-A</i>)	207,208
		Yes-associated protein (<i>YAP</i>)	205,206
	Autophagy regulating proteins	Autophagy-related 5 (<i>ATG5</i>)	196
		Mammalian target of rapamycin (<i>MTOR</i>)	197
		Prorenin receptor (<i>PRR</i>)	198–200
		Class III phosphoinositide 3-kinase/Vacuolar protein sorting 34 (<i>PIK3C3/VPS34</i>)	201,202

Means of injury	Category	Agent/Molecule/Gene	References
Genetic modification	Signaling pathway activation	β -catenin (<i>CTNNB1</i>)	209
		Notch intracellular domain 1 (<i>ICN1</i>)	210
		Integrin-linked kinase (<i>ILK</i>)	211–213
		Negative factor (<i>NEF</i>)	214,215
		Notch's intracellular domain (<i>NOTCH-IC</i>)	216
		Septin (<i>SEPT7</i>)	217
		Transforming growth factor β (<i>TGF-β</i>)	218
		Tuberous sclerosis complex 1 (<i>TSC1</i>)	219
		Vpr-binding protein (<i>VPR</i>)	215
		Wingless-type MMTV integration site family 1 (<i>WNT1</i>)	220
	Signaling pathway reduction	Akt2 (<i>AKT2</i>)	221
		PINCH-1-binding ankyrin repeat domain of ILK (<i>ANK</i>)	222
		Angiotensin II receptor 2 (<i>AT2</i>)	223
		β -catenin (<i>CTNNB1</i>)	209,224,225
		Diaphanous interacting protein (<i>DIP</i>)	226
		Dickkopf WNT signaling pathway inhibitor 1 (<i>DKK1</i>)	209,220,225
		Insulin-like growth factor-I receptor (<i>IGF-IR</i>)	195,227–229
		Insulin receptor (<i>INSR</i>)	195,227,229
		NF- κ B essential modulator (<i>NEMO</i>)	230,231
		Notch-1 (<i>NOTCH1</i>)	232
		Notch-3 (<i>NOTCH3</i>)	233
		3-phosphoinositide-dependent kinase-1 (<i>PKD1</i>)	234
		Rapamycin-sensitive adaptor protein of mTOR (<i>RAPTOR</i>)	219,235
		Recombining binding protein suppressor of hairless (<i>RBPSUH</i>)	216
		Rapamycin-insensitive subunit of mTOR (<i>RICTOR</i>)	221,235
		SH2-domain-containing inositol polyphosphate 5-phosphatase 2 (<i>SHIP2</i>)	236
		SMAD family member 2/3 (<i>SMAD2</i> , <i>SMAD3</i>)	237
		Signal transducer and activator of transcription 3 (<i>STAT3</i>)	238–240
	Slit diaphragm-associated proteins	CD2-associated protein (<i>CD2AP</i>)	63,92,130,131
		Cysteine-rich motor neuron 1 (<i>CRIM1</i>)	142
		FAT atypical cadherin 1 (<i>FAT1</i>)	143
		Fyn proto-oncogene (<i>FYN</i>)	92,144,145
		IQ domain GTPase-activating protein 1 (<i>IQGAP1</i>)	146,147
		MAGUK inverted 2 (<i>MAGI-2</i>)	148
		Myosin 1c (<i>MYO1C</i>)	149
		Myosin 1e (<i>MYO1E</i>)	150–153
		Nck adaptor protein 1/2 (<i>NCK1</i> , <i>NCK2</i>)	86,132,133
		Nephrin (<i>NPHS1</i>)	124–126
		Kin of IRRE-like 1 (<i>NEPH1</i>)	126,154
		Podocin (<i>NPHS2</i>)	127–129
		Transient receptor potential cation channel 6 (<i>TRPC6</i>)	134–141
		Zonula occludens 1 (<i>ZO-1</i>)	155
	Podocyte polarity	A typical protein kinase C lambda/iota (<i>aPKCλ/i</i>)	161–163
		Cdc42 (<i>CDC42</i>)	119,160
		Glucosamine uridine diphospho-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (<i>GNE</i>)	89
		Podocalyxin (<i>PC</i>)	156,157
		Protein-tyrosine phosphatase receptor o/Glomerular epithelial protein 1 (<i>PTPRO/GLEPP1</i>)	158,159
		Van Gogh-like (planar cell polarity) protein 2 (<i>VANGL2</i>)	164–166

Means of injury	Category	Agent/Molecule/Gene	References
Genetic modification	GBM-associated proteins and enzymes	CD9 (<i>CD9</i>)	171
		CD151 (<i>CD151</i>)	172–175
		Type IV collagen $\alpha 3/\alpha 4/\alpha 5$ (<i>COL4A3</i> , <i>COL4A4</i> , and <i>COL4A5</i>)	176–178
		Discoidin domain receptor 1 (<i>DDR1</i>)	179
		Glypican 5 (<i>GPC5</i>)	180
		Integrin-linked kinase (<i>ILK</i>)	168,181,182
		Integrin $\alpha 3$ (<i>ITGA3</i>)	27,167
		Integrin $\beta 1$ (<i>ITGB1</i>)	168,169
		Integrin $\beta 4$ (<i>ITGB4</i>)	170
		Laminin $\beta 2$ (<i>LAMB2</i>)	183–186
		N-deacetylase/N-sulfotransferase (<i>NDST1</i>)	187
		RAP1 GTPase-activating protein (<i>RAP1GAP</i>)	188
		Talin 1 (<i>TLN1</i>)	189

GBM, glomerular basement membrane.

of a healthy glomerulus. Administration of lipopolysaccharides (LPS) is an example of such a reversible model^{57–59}. LPS trigger podocyte FP effacement and transient proteinuria within 24 hours, which return to baseline after 3 days⁵⁸. Podocytes sense LPS by Toll-like receptor 4 (TLR-4) and this pro-inflammatory response upregulates expression of the co-stimulatory molecule B7-1⁵⁷ and the urokinase-type plasminogen activator receptor (uPAR)⁶⁰. LPS also induces the cytosolic variant of cathepsin L (CatL) enzyme⁶¹, indicating that CatL upregulation in podocytes is associated with the development of proteinuria in mice through a mechanism that involves the cleavage of large GTPase dynamin⁶¹, synaptopodin⁶², and CD2-associated protein (CD2AP)⁶³. In a recent study, we reported that the modification of intracellular pH by glutamine uptake was a protective mechanism of cultured mouse podocytes against cytosolic CatL activity, which was markedly elevated under the disease state⁶⁴. Treatment of cultured human podocytes with TLR-3 immunostimulant polyinosinic-polycytidylic acid (polyIC) induces CatL mRNA and simultaneously downregulates podocyte marker protein synaptopodin⁶⁵, suggesting that polyIC may follow an injury pathway similar to that of LPS.

Another means of podocyte injury are subepithelial immune complexes developing as a result of circulating antibodies, which damage or activate podocytes through complement-dependent processes. A number of signaling pathways have been implicated in complement-mediated podocyte injury^{66–69}, in which sublethal concentrations of complement produce a pronounced but reversible disruption of the actin cytoskeleton and associated focal contacts⁷⁰. Other intracellular events include endoplasmic reticulum (ER) stress, production of ROS, and proteases. Focusing on immunologically induced glomerular injury, podocytes also respond to immunologic processes particularly targeting GBM. Passive administration of heterologous sera containing cross-reacting antibodies against the GBM results in vacuolization of podocytes, focal detachment of podocytes from GBM, and immediate

onset of glomerulosclerosis with crescent formation^{71–78} consistent with a crosstalk between podocytes and the immune system.

Distortion of glomerular charge selectivity by neutralization of the negative charges on podocytes and SDs with polycation protamine sulfate (PS) causes FPs to broaden *in vivo*^{30,79–81} and stress fibers to disintegrate *in vitro*⁸² in a calcium-dependent manner^{83,84}. These physiological changes happen within 15 minutes following PS treatment and can be reversed by reperfusion with heparin for another 15 minutes^{81,85,86}. PS is also responsible for the phosphorylation of SD protein nephrin^{81,86} and focal adhesion complex protein Cas⁸¹. On the other hand, protamine had little or no effect on the sieving coefficient (also referred to as fractional clearance) of bovine serum albumin once added to neutralize GBM polyanions, a finding that downplays the contribution of GBM to the charge selectivity exhibited by the glomerular filtration barrier⁸⁷. A similar structural alteration can be induced by polycation poly-L-lysine⁸⁵, by removal of the sialic acid^{11,88}, or by mutation in glucosamine (UDP-*N*-acetyl)-2-epimerase/*N*-acetylmannosamine kinase (*GNE*), the rate-limiting enzyme of sialic acid biosynthesis⁸⁹. Patients with mutations in *GNE*, however, develop the rare muscle disease HIBM (hereditary inclusion body myopathy) and never get kidney disease⁸⁹, highlighting the differences between mice and humans in this pathway in the kidney.

Mutations, abnormalities, or genetic overexpression or deletion in genes encoding podocyte proteins, which are the regulators of actin cytoskeleton such as synaptopodin (*SYNPO*)^{90–92}, α -actinin 4 (*ACTN4*)^{93–96}, dynamin (*DYN*)^{61,97,98}, aarF domain-containing kinase 4 (*ADCK4*)⁹⁹, anillin (*ANLN*)¹⁰⁰, apolipoprotein L1 (*APOLI*)¹⁰¹, RhoA-activated Rac1 GTPase-activating protein 24 (*ARHGAP24*)¹⁰², Rho guanine nucleotide dissociation inhibitor- α (*ARHGDI*)^{103–105}, claudin-1 (*CLDN1*)¹⁰⁶, chloride intracellular channel 5A (*CLIC5A*)¹⁰⁷, cofilin-1 (*CFLI*)^{108,109}, ezrin (*EZR*)¹¹⁰, inverted formin 2 (*INF2*)^{111–114}, kidney ankyrin repeat-containing

protein (*KANK1*, *KANK2*, *KANK4*)¹¹⁵, neuronal Wiskott-Aldrich syndrome protein (N-WASP)¹¹⁶, class II phosphoinositide 3-kinase C2 α (*PI3KC2 α*)¹¹⁷, phospholipase C ϵ 1 (*PLCE1*)¹¹⁸, Rho family small GTP-binding protein Rac1 (*RAC1*)^{119,120}, raphilin 1 (*RHPN1*)¹²¹, schwannomin interacting protein 1 (*SCHIP1*)¹²², and WT1-interacting protein (*WTIP*)¹²³, and the ones that are associated with SD complex, including nephrin (*NPHS1*)^{124–126}, podocin (*NPHS2*)^{127–129}, CD2-associated protein (*CD2AP*)^{63,92,130,131}, Nck adaptor protein 1/2 (*NCK1*, *NCK2*)^{86,132,133}, transient receptor potential cation channel 6 (*TRPC6*)^{134–141}, cysteine-rich motor neuron 1 (*CRIMI*)¹⁴², FAT atypical cadherin 1 (*FAT1*)¹⁴³, Fyn proto-oncogene (*FYN*)^{92,144,145}, IQ domain GTPase-activating protein 1 (*IQGAP1*)^{146,147}, MAGUK Inverted 2 (*MAGI-2*)¹⁴⁸, myosin 1c (*MYO1C*)¹⁴⁹, myosin 1e (*MYO1E*)^{150–153}, kin of IRRE like 1 (*NEPH1*)^{126,154}, and zonula occludens 1 (*ZO-1*)¹⁵⁵, leads to proteinuric diseases owing to the disruption of filtration barrier and rearrangement of actin cytoskeleton.

Likewise, glomerular filtration barrier is impaired if the podocyte apical membrane domain proteins maintaining the negative surface charge are lost or transferred including podocalyxin (*PC*)^{156,157}, protein-tyrosine phosphatase receptor o/glomerular epithelial protein 1 (*PTPRO/GLEPP1*)^{158,159}, cdc42 (*CDC42*)^{119,160}, atypical protein kinase Clambda/iota (*aPKC λ /i*)^{161–163}, glucosamine uridine diphospho-*N*-acetylglucosamine-2-epimerase/*N*-acetylmannosamine kinase (*GNE*)⁸⁹, and Van Gogh-like (planar cell polarity) protein 2 (*VANGL2*)^{164–166}. Highlighting the importance of glomerular capillary wall assembly, manipulating or deleting the genes implicated in the adhesion of podocytes to GBM components such as integrin α 3 (*ITGA3*)^{27,167}, integrin β 1 (*ITGB1*)^{168,169}, integrin β 4 (*ITGB4*)¹⁷⁰, CD9 (*CD9*)¹⁷¹, CD151 (*CD151*)^{172–175}, type IV collagen α 3/ α 4/ α 5 (*COL4A3*, *COL4A4*, *COL4A5*)^{176–178}, discoidin domain receptor 1 (*DDR1*)¹⁷⁹, glypican 5 (*GPC5*)¹⁸⁰, integrin-linked kinase (*ILK*)^{168,181,182}, laminin β 2 (*LAMB2*)^{183–186}, *N*-deacetylase/*N*-sulfotransferase (*NDST1*)¹⁸⁷, RAP1 GTPase-activating protein (*RAP1GAP*)¹⁸⁸, and talin 1 (*TLN1*)¹⁸⁹ causes disorganization of podocyte cytoskeletal architecture, leading to deformation in glomerular filtration.

The involvement of lysosome membrane protein 2 (*SCARB2/LIMP2*)¹⁹⁰ in the maintenance of podocyte structure and mitochondrial proteins coenzyme Q₂ (*COQ2*)¹⁹¹, coenzyme Q₆ (*COQ6*)¹⁹², Mpv17 (*MPV17*)¹⁹³, mitochondrial tRNA leucine 1 (*MTTL1*)¹⁹⁴, and prohibitin ring complex subunit prohibitin-2 (*PHB2*)¹⁹⁵ in the redox state of podocyte is reported in genetic studies. Podocyte-specific deletion of autophagy-related 5 (*ATG5*)¹⁹⁶, mammalian target of rapamycin (*MTOR*)¹⁹⁷, prorenin receptor (*PRR*)^{198–200}, and class III phosphoinositide 3-kinase/vacuolar protein sorting 34 (*PIK3C3/VPS34*)^{201,202} disrupts intracellular vesicle trafficking and impairs autophagic flux. Ablation of dendrin (*DDN*)²⁰³ improves renal survival in progressive glomerulosclerosis, whereas knockdown of survivin (*BIRC5*)²⁰⁴, a member of the inhibitor of apoptosis protein family, and Yes-associated protein (*YAP*)^{205,206}, a downstream target of Hippo kinases, induces podocyte apoptosis. Podocyte-specific knockout mice for vascular endothelial growth factor A (*VEGF-A*) demonstrated a key role for VEGF-A signaling for the establishment and maintenance of a normal glomerular filtration barrier²⁰⁷ as well as mesangial cell survival and differentiation²⁰⁸.

A tremendous number of genetic studies were carried out to reveal the biological role of various pathways in podocytes. Regulatory genes, including β -catenin (*CTNNB1*)²⁰⁹, Notch intracellular domain 1 (*ICN1*)²¹⁰, *ILK*^{211–213}, negative factor (*NEF*)^{214,215}, Notch's intracellular domain (*NOTCH-IC*)²¹⁶, septin (*SEPT7*)²¹⁷, transforming growth factor- β (*TGF- β*)²¹⁸, tuberous sclerosis complex 1 (*TSC1*)²¹⁹, vpr-binding protein (*VPR*)²¹⁵, and wingless-type MMTV integration site family 1 (*WNT1*)²²⁰, are used as genetic switches to turn on (activate) a specific signaling pathway. There are also studies aiming to shut down (repress) a particular pathway targeting the genes such as Akt2 (*AKT2*)²²¹, PINCH-1-binding ankyrin repeat domain of ILK (*ANK*)²²², angiotensin II receptor 2 (*AT2*)²²³, *CTNNB1*^{209,224,225}, diaphanous interacting protein (*DIP*)²²⁶, dickkopf WNT signaling pathway inhibitor 1 (*DKK1*)^{209,220,225}, insulin-like growth factor-I receptor (*IGF-IR*)^{195,227–229}, insulin receptor (*INSR*)^{195,227,229}, NF- κ B essential modulator (*NEMO*)^{230,231}, Notch-1 (*NOTCH1*)²³², Notch-3 (*NOTCH3*)²³³, 3-phosphoinositide-dependent kinase-1 (*PDK1*)²³⁴, rapamycin-sensitive adaptor protein of mTOR (*RAPTOR*)^{219,235} and rapamycin-insensitive subunit of mTOR (*RICTOR*)^{221,235}, recombining binding protein suppressor of hairless (*RBP5UH*)²¹⁶, SH2-domain-containing inositol polyphosphate 5-phosphatase 2 (*SHIP2*)²³⁶, SMAD family member 2/3 (*SMAD2*, *SMAD3*)²³⁷, and signal transducer and activator of transcription 3 (*STAT3*)^{238–240}.

Currently, there is great interest in research into transcriptional regulation of gene expression patterns during development and differentiation of podocytes²⁴¹. Genetic studies and analysis of mutations in genes encoding transcription factors provide a comprehensive approach in characterizing the functional role of transcription factors. Alterations in c-Maf-inducing protein (*CMIP*)^{242,243}, forkhead box C2 (*FOXC2*)²⁴⁴, hypoxia-inducible factor 1 α (*HIF1A*)^{245–247}, Krüppel-like factor 6 (*KLF6*)²⁴⁸, LIM homeobox transcription factor 1 β (*LMX1B*)^{249–254}, v-Maf avian musculoaponeurotic fibrosarcoma oncogene homolog B (*MAFB*)^{255,256}, nuclear factor of activated T cells (NFAT)^{257,258}, paired box gene 2 (*PAX2*)²⁵⁹, podocyte-expressed 1/transcription factor 21 (*POD1/TCF21*)²⁶⁰, peroxisome proliferator-activated receptor- α (*PPARA*)²⁶¹, Snail family zinc finger 1 (*SNAIL*)^{262,263}, Wilm's tumor 1 (*WT-1*)^{264–268}, zinc finger E-box-binding homeobox 2 (*ZEB2*)²⁶⁹, and zinc fingers and homeoboxes 1/2/3 (*ZHX1*, *ZHX2*, and *ZHX3*)²⁷⁰ were studied to enforce a particular cell fate by stimulating or suppressing the related genes.

In addition to these molecules, factors, and genes implicating various means of podocyte injury, there are proteins or agents such as angiopoietin-like 3 (*ANGPTL3*)²⁷¹, B7-1 (*CD80*)^{272,273}, cytosolic CatL^{61–64}, glucose^{273–277}, glutamine⁶⁴, insulin²²⁷, integrin β 3 (*ITGB3*)^{60,278}, tumor necrosis factor- α (TNF- α)^{279–281}, transient receptor potential cation channel 5/6 (*TRPC5* and *TRPC6*)²⁸², and uPAR⁶⁰ that are involved in the regulation of podocyte cytoskeleton. In some cases, this cytoskeletal disaggregation and the associated activation of certain pathways (including tumor suppressor protein p53 and caspases) lead to podocyte loss (*in vitro*) and detachment from GBM (*in vivo*). Seminal studies have shown that apoptotic stimuli are mediated by albumin^{283–285}, aldosterone^{286–288}, angiopoietin-like3 (*ANGPTL3*)²⁸⁹, angiotensin II^{290–294}, fatty acids^{295–297}, glucose^{232,294,298}, IGF-binding protein-3 (*IGFBP-3*)²⁹⁹, oxidized

low-density lipoprotein (LDL)³⁰⁰, and TGF- β 1^{237,301–304}. Angiotensin II³⁰⁵ and glucose³⁰⁶ might also induce podocyte autophagic processes as evidenced by the presence of the increased number of autophagosomes and autophagic genes such as LC3-2 and beclin-1. Under specific conditions, podocyte injury leads to a phenotypic conversion, where podocytes lose their epithelial features such as nephrin, P-cadherin, and ZO-1 while acquiring mesenchymal markers such as desmin, fibroblast-specific protein-1 (FSP-1), α -smooth muscle actin (α -SMA), vimentin, type I collagen, and fibronectin³⁰⁷. This process is referred to as podocyte's epithelial-mesenchymal transition (EMT) and is driven in some cases by endothelin-1 (ET-1)²⁶³, ILK²¹², PAN²⁶², and TGF- β 1³⁰⁸. When infected by human immunodeficiency virus 1 (HIV-1) NEF protein^{309,310} or treated by TNF- α ³¹¹, the podocyte gives a proliferative response marked by the loss of differentiation markers such as synaptopodin, WT-1, and GLEPP-1 and the subsequent expression of the proliferation markers such as podocyte G₁ cyclin, cyclin A, cyclin D1, and Ki-67. There is evidence that non-cytokine-soluble factors such as soluble urokinase-type plasminogen activator receptor (suPAR)²⁷⁸ cause podocyte FP effacement and proteinuria via a β 3 integrin-dependent mechanism but that circulating sialylated ANGPTL4³¹² reduces proteinuria via an endothelial β 5 integrin-dependent mechanism. By contrast, podocyte-secreted hypo-sialylated ANGPTL4 causes proteinuria via interactions with the GBM³².

Although these complex regulatory mechanisms imply the vulnerability of podocytes, a variety of factors support podocyte differentiation and survival, including activated protein C (APC)^{313,314}, bone morphogenetic protein-7 (BMP7)^{277,299,315}, insulin-like growth factor-II (IGF-II)²²⁸, VEGF-A^{316–318}, and vascular endothelial growth factor C (VEGF-C)^{318,319}.

Podocytes in glomerular disease pathology

Although the podocyte injury is not the only cause of major glomerular diseases, a stable podocyte architecture with interdigitating FPs connected by highly specialized filtration slits is essential for the maintenance and proper function of the glomerular filtration barrier. Both experimental and clinical studies have indicated a pivotal role of podocyte injury in the development and progression of glomerular diseases.

A number of different conditions and health risk factors can result in glomerular disease. Nephrotic syndrome or glomerulonephritis (i.e., malfunction of glomerular filter) may be a direct result of an infection or accumulation of toxic agents in kidneys, or (podocyte- and GBM-associated) genetic defects, or may be due to a secondary insult such as a pre-existing disease occurring in the body^{320–322}. This represents the conventional approach to classification of glomerular diseases, which generally meets the needs of nephrologists.

The most common cause of primary glomerular disease in adults is focal segmental glomerulosclerosis (FSGS), which is defined by the scarring (sclerosis) of some but not all of the glomeruli (focal) that involves only a section of the affected glomeruli (segmental) by light microscopy of a renal biopsy specimen. In most cases, distinguishing primary (idiopathic) FSGS from the genetic form of FSGS associated with mutations in essential podocyte proteins^{323,324} or secondary FSGS (linked to a variety of conditions, including

viral infections, drug toxicity, or previous glomerular injury)³²⁵ is challenging; however, it has been proven that this heterogeneous lesion results from podocyte injury^{20,50,326,327}. Once the integrity of podocyte FPs is lost, podocytes start to detach from underlying GBM at certain sites revealing bare areas of glomerular capillary surface. Later, these bare areas of GBM contact the Bowman's capsule and form synechia, which represents the earliest committed FSGS lesion. This sequence of pathological events eventually leads to the development of more lesions and progression to glomerulosclerosis³²⁸. Recurrence of FSGS in renal transplant recipients has given rise to the existence of permeability or circulating factor(s) acting on podocytes as the cause of primary FSGS³²⁹. To date, a few plasma factors have been proposed³³⁰ but most of these have been found to be non-specific to FSGS serum/plasma³³¹. Recently, suPAR was found to be associated with FSGS; for example, two thirds of patients with primary FSGS exhibited high levels of suPAR and those with the highest levels had a greater chance of recurrence after transplantation²⁷⁸. In support of this, our group found that higher suPAR levels at baseline are independently associated with faster decline in eGFR and suPAR in plasma can predict risk of developing chronic kidney disease (CKD) in healthy people up to five years before its onset³³².

Contrary to FSGS, in which podocytes are lost in the areas of sclerosis, minimal change disease (MCD) is a reversible disorder with normal histology and does not cause podocyte depletion. Diffuse effacement of podocyte FPs (accompanied by condensation of the actin-based cytoskeleton but not associated with reduction of any key podocyte-specific protein except podocyte alpha-dystroglycan³³³) and loss of GBM charge are among the classic features of MCD. All of these changes, and the development of selective proteinuria, are attributed to the secretion from podocytes of a form of ANGPTL4 that lacks sialic acid residues^{32,334}.

An FSGS-related but morphologically distinct phenotype was observed when podocytes are infected with HIV^{335,336} or induced by infections, drugs, autoimmune diseases, or organ transplants^{337–339}. This phenotype is described as collapsing glomerulopathy (CG) and is characterized by extensive loss of mature podocyte markers, severe FP effacement, and focal detachment together with the collapse of the capillary loops. Importantly, podocytes re-enter the cell cycle, become capable of proliferating, and lead to the formation of crescents filling the Bowman's space, making CG structurally distinct from other forms of FSGS^{214,309,340}. If left untreated, HIV-1-associated nephropathy progresses to end-stage renal disease within weeks to months, whereas the combined antiretroviral therapy, which blocks HIV-1 replication, limits podocyte hyperplasia and hypertrophy and brings podocytes back to differentiation state³⁴¹. Studies using animal models have demonstrated that CG can be ameliorated by using cell-cycle inhibitors³⁴² or by activating transcription factors involved in podocyte differentiation³⁴³; however, full recovery from CG is scarce³⁴⁴.

The immunoglobulin A (IgA) nephropathy (IgAN), which is the most prevalent primary chronic glomerular disease worldwide³⁴⁵, exhibits significant heterogeneity in terms of histopathologic features and clinical outcomes³⁴⁶. Emerging data suggest that mesangial deposition of IgA1 immune complexes leads to podocyte necrosis

and detachment from the GBM^{347,348} with the subsequent reduction in nephrin mRNA³⁴⁹.

Obesity-related hypertension and diabetes have become epidemic health problems worldwide and major risk factors for the development of CKD³⁵⁰. High glucose altered podocyte actin assembly *in vitro*³⁵¹, high blood glucose (hyperglycemia) induced podocyte apoptosis via the ROS-dependent pathway in obese rodents²⁹⁸, and podocyte density and number decreased in patients with obesity-related glomerulopathy³⁵².

Targeting podocytes as renal-specific therapy

Human kidney has been considered a terminally differentiated organ with minimal cellular turnover and limited capacity for repair, suggesting that kidney injuries carrying severe consequences have limited treatment options. The goal of clinical nephrologists and renal researchers should be to identify the renal protection mechanism and to develop strategies for the treatment of kidney or various renal compartments of which kidney is composed. Podocytes are probably the most likely candidate cell population to be analyzed on a molecular level since these intricate cells are the most vulnerable component of the glomerular filtration network even during early stages of injury and serve as hallmarks of a state of glomerular disease³⁵³. Owing to their post-mitotic nature, podocytes have a limited capacity for cell division and do not regenerate in response to injury and loss³⁵⁴. This leads to rapid progression of glomerular diseases unless treated. Regardless of the diverse origins of glomerular diseases, podocytes are critical determinants of outcome for all glomerular diseases, which makes podocytes a unique model for monitoring and investigating disease progression³⁵⁵.

Therefore, there has been a pronounced shift toward podocyte proteins as therapeutic targets in the last decade³⁵⁶. Sialic acid and its precursors show efficacy in MCD³² and diabetic nephropathy³⁵⁷. Mutant forms of human *ANGPTL4* reduce proteinuria without causing hypertriglyceridemia in FSGS and diabetic nephropathy^{312,357}. Calcineurin inhibitor cyclosporine A (CsA) stabilizes of the actin cytoskeleton and stress fibers in podocytes by blocking the calcineurin-mediated phosphorylation and CatL-facilitated degradation of synaptopodin⁶². As mentioned earlier, suPAR, which activates integrin $\alpha\beta3$ independent of uPAR, has been suggested as an FSGS factor²⁷⁸. A specific inhibitor of integrin $\alpha\beta3$, cyclo-RGDfV, ameliorates proteinuria in mouse models of nephrotic syndrome by

directly targeting the upregulated integrin $\alpha\beta3$ on podocytes⁶⁰. CD20 antibody rituximab binds to sphingomyelin phosphodiesterase acid-like 3b (SMPDL-3b) and stabilizes the structure and function of podocytes treated with the sera of patients with recurrent FSGS³⁵⁸. Abatacept blocks the interaction of B7-1 (CD80) with cytoskeletal protein talin and thereby stabilizes $\beta1$ -integrin activity and prevents podocyte motility³⁵⁹. However, these results have been subjected to criticism since uncertainties still remain, preventing us from being too optimistic about the general efficacy of abatacept^{360–362}. The GTPase dynamin, which promotes endocytosis and regulates actin cytoskeleton^{61,97}, is induced by small-molecule Bis-T-23 as a potential therapeutic approach³⁶³. Bis-T-23 effectively promotes dynamin assembly into higher-order structures and increases actin polymerization in injured podocytes³⁶⁴.

Molecular analysis of podocytes will lead to a better understanding of disease mechanisms and therefore may enable the identification of targets for early-onset diagnostics and disease treatment. In this context, cell-based high-throughput drug screening assays quantifying the phenotypic changes in podocytes (specifically changes in morphology, F-actin cytoskeleton, focal adhesions, cell volume, and so on) offer great value for the discovery of chemotherapeutic agents. Recently, a podocyte cell-based phenotypic assay was developed and applied to identify novel podocyte-protective small molecules and establish specific drug delivery strategies³⁶⁴.

The possibilities of targeting podocytes and thereby affecting kidney disease and progression early in the course set high expectations and hopefully will provide a significant benefit to human health in the future.

Competing interests

Jochen Reiser has pending and issued patents on novel strategies for kidney therapeutics and stands to gain royalties from their commercialization. He is co-founder of TRISAQ (Miami, FL, USA), a biotechnology company in which he has financial interest, including stock. MA declares that he has no competing interests.

Grant information

The author(s) declared that no grants were involved in supporting this work.

References

- Pavenstädt H, Kriz W, Kretzler M: **Cell biology of the glomerular podocyte.** *Physiol Rev.* 2003; **83**(1): 253–307.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Andrews PM: **Investigations of cytoplasmic contractile and cytoskeletal elements in the kidney glomerulus.** *Kidney Int.* 1981; **20**(5): 549–62.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Kriz W, Hackenthal E, Nobiling R, et al.: **A role for podocytes to counteract capillary wall distension.** *Kidney Int.* 1994; **45**(2): 369–76.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Ichimura K, Kurihara H, Sakai T: **Actin filament organization of foot processes in rat podocytes.** *J Histochem Cytochem.* 2003; **51**(12): 1589–600.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Reiser J, Kriz W, Kretzler M, et al.: **The glomerular slit diaphragm is a modified adherens junction.** *J Am Soc Nephrol.* 2000; **11**(1): 1–8.
[PubMed Abstract](#)
- Fukasawa H, Bornheimer S, Kudlicka K, et al.: **Slit diaphragms contain tight junction proteins.** *J Am Soc Nephrol.* 2009; **20**(7): 1491–503.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Huber TB, Benzing T: **The slit diaphragm: a signaling platform to regulate podocyte function.** *Curr Opin Nephrol Hypertens.* 2005; **14**(3): 211–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
- George B, Holzman LB: **Signaling from the podocyte intercellular junction to the actin cytoskeleton.** *Semin Nephrol.* 2012; **32**(4): 307–18.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

9. Grahammer F, Schell C, Huber TB: **The podocyte slit diaphragm—from a thin grey line to a complex signalling hub.** *Nat Rev Nephrol.* 2013; 9(10): 587–98.
[PubMed Abstract](#) | [Publisher Full Text](#)
10. Kerjaschki D, Sharkey DJ, Farquhar MG: **Identification and characterization of podocalyxin—the major sialoprotein of the renal glomerular epithelial cell.** *J Cell Biol.* 1984; 98(4): 1591–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
11. Gelberg H, Healy L, Whiteley H, et al.: **In vivo enzymatic removal of alpha 2→6-linked sialic acid from the glomerular filtration barrier results in podocyte charge alteration and glomerular injury.** *Lab Invest.* 1996; 74(5): 907–20.
[PubMed Abstract](#)
12. Satchell SC, Braet F: **Glomerular endothelial cell fenestrations: an integral component of the glomerular filtration barrier.** *Am J Physiol Renal Physiol.* 2009; 296(5): F947–56.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. Kretzler M: **Regulation of adhesive interaction between podocytes and glomerular basement membrane.** *Microsc Res Tech.* 2002; 57(4): 247–53.
[PubMed Abstract](#) | [Publisher Full Text](#)
14. Farquhar MG: **The glomerular basement membrane: not gone, just forgotten.** *J Clin Invest.* 2006; 116(8): 2090–3.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
15. Tryggvason K, Wartiovaara J: **How does the kidney filter plasma? Physiology (Bethesda).** 2005; 20(2): 96–101.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Menon MC, Chuang PY, He CJ: **The glomerular filtration barrier: components and crosstalk.** *Int J Nephrol.* 2012; 2012: 749010.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Haraldsson B, Nyström J, Deen WM: **Properties of the glomerular barrier and mechanisms of proteinuria.** *Physiol Rev.* 2008; 88(2): 451–87.
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Mundel P, Reiser J: **Proteinuria: an enzymatic disease of the podocyte?** *Kidney Int.* 2010; 77(7): 571–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Endlich K, Kriz W, Witzgall R: **Update in podocyte biology.** *Curr Opin Nephrol Hypertens.* 2001; 10(3): 331–40.
[PubMed Abstract](#)
20. Asanuma K, Mundel P: **The role of podocytes in glomerular pathobiology.** *Clin Exp Nephrol.* 2003; 7(4): 255–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
21. Garg P, Holzman LB: **Podocytes: gaining a foothold.** *Exp Cell Res.* 2012; 318(9): 955–63.
[PubMed Abstract](#) | [Publisher Full Text](#)
22. Barisoni L, Schnaper HW, Kopp JB: **Advances in the biology and genetics of the podocytopathies: implications for diagnosis and therapy.** *Arch Pathol Lab Med.* 2009; 133(2): 201–16.
[PubMed Abstract](#) | [Free Full Text](#)
23. Bierzynska A, Soderquest K, Koziell A: **Genes and podocytes - new insights into mechanisms of podocytopathy.** *Front Endocrinol (Lausanne).* 2015; 5: 226.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
24. Bertram JF, Messina A, Ryan GB: **In vitro effects of puromycin aminonucleoside on the ultrastructure of rat glomerular podocytes.** *Cell Tissue Res.* 1990; 260(3): 555–63.
[PubMed Abstract](#) | [Publisher Full Text](#)
25. Whiteside CI, Cameron R, Munk S, et al.: **Podocytic cytoskeletal disaggregation and basement-membrane detachment in puromycin aminonucleoside nephrosis.** *Am J Pathol.* 1993; 142(5): 1641–53.
[PubMed Abstract](#) | [Free Full Text](#)
26. Kim YH, Goyal M, Kurnit D, et al.: **Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat.** *Kidney Int.* 2001; 60(3): 957–68.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Reiser J, Oh J, Shirato I, et al.: **Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin L and alpha3 integrin.** *J Biol Chem.* 2004; 279(33): 34827–32.
[PubMed Abstract](#) | [Publisher Full Text](#)
28. Marshall CB, Pippin JW, Krofft RD, et al.: **Puromycin aminonucleoside induces oxidant-dependent DNA damage in podocytes in vitro and in vivo.** *Kidney Int.* 2006; 70(11): 1962–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
29. Fukuda H, Hidaka T, Takagi-Akiba M, et al.: **Podocin is translocated to cytoplasm in puromycin aminonucleoside nephrosis rats and in poor-prognosis patients with IgA nephropathy.** *Cell Tissue Res.* 2015; 360(2): 391–400.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. Kurihara H, Anderson JM, Kerjaschki D, et al.: **The altered glomerular filtration slits seen in puromycin aminonucleoside nephrosis and protamine sulfate-treated rats contain the tight junction protein ZO-1.** *Am J Pathol.* 1992; 141(4): 805–16.
[PubMed Abstract](#) | [Free Full Text](#)
31. Zhao L, Yaoita E, Nameta M, et al.: **Claudin-6 localized in tight junctions of rat podocytes.** *Am J Physiol Regul Integr Comp Physiol.* 2008; 294(6): R1856–62.
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Clement LC, Avila-Casado C, Macé C, et al.: **Podocyte-secreted angiotensin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome.** *Nat Med.* 2011; 17(1): 117–22.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
33. Wada T, Pippin JW, Marshall CB, et al.: **Dexamethasone prevents podocyte apoptosis induced by puromycin aminonucleoside: role of p53 and Bcl-2-related family proteins.** *J Am Soc Nephrol.* 2005; 16(9): 2615–25.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
34. Wada T, Pippin JW, Nangaku M, et al.: **Dexamethasone's prosurvival benefits in podocytes require extracellular signal-regulated kinase phosphorylation.** *Nephron Exp Nephrol.* 2008; 109(1): e8–19.
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Shibata S, Nagase M, Fujita T: **Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling.** *J Am Soc Nephrol.* 2006; 17(3): 754–64.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
36. Eto N, Wada T, Inagi R, et al.: **Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression.** *Kidney Int.* 2007; 72(4): 455–63.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
37. Takeuchi S, Hiromura K, Tomioka M, et al.: **The immunosuppressive drug mizoribine directly prevents podocyte injury in puromycin aminonucleoside nephrosis.** *Nephron Exp Nephrol.* 2010; 116(1): e3–10.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
38. Pawluczyk IZ, Najafabadi MG, Brown JR, et al.: **Sialic acid supplementation ameliorates puromycin aminonucleoside nephrosis in rats.** *Lab Invest.* 2015; 95(9): 1019–28.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
39. Shimo T, Adachi Y, Yamanouchi S, et al.: **A novel nuclear factor κB inhibitor, dehydroxymethylpoxiquinomicin, ameliorates puromycin aminonucleoside-induced nephrosis in mice.** *Am J Nephrol.* 2013; 37(4): 302–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
40. Bertani T, Poggi A, Pozzoni R, et al.: **Adriamycin-induced nephrotic syndrome in rats: sequence of pathologic events.** *Lab Invest.* 1982; 46(1): 16–23.
[PubMed Abstract](#)
41. Okuda S, Oh Y, Tsuruda H, et al.: **Adriamycin-induced nephropathy as a model of chronic progressive glomerular disease.** *Kidney Int.* 1986; 29(2): 502–10.
[PubMed Abstract](#) | [Publisher Full Text](#)
42. Rossmann P, Matousov K, Bohdanecká M: **Experimental adriamycin nephropathy. Fine structure, morphometry, glomerular polyanion, and cell membrane antigens.** *J Pathol.* 1993; 169(1): 99–108.
[PubMed Abstract](#) | [Publisher Full Text](#)
43. Wang Y, Wang YP, Tay YC, et al.: **Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events.** *Kidney Int.* 2000; 58(4): 1797–804.
[PubMed Abstract](#) | [Publisher Full Text](#)
44. Zojal C, Garcia PB, Rota C, et al.: **Mesenchymal stem cell therapy promotes renal repair by limiting glomerular podocyte and progenitor cell dysfunction in adriamycin-induced nephropathy.** *Am J Physiol Renal Physiol.* 2012; 303(9): F1370–81.
[PubMed Abstract](#) | [Publisher Full Text](#)
45. Chen A, Wei CH, Sheu LF, et al.: **Induction of proteinuria by adriamycin or bovine serum albumin in the mouse.** *Nephron.* 1995; 69(3): 293–300.
[PubMed Abstract](#) | [Publisher Full Text](#)
46. Chen A, Sheu LF, Ho YS, et al.: **Experimental focal segmental glomerulosclerosis in mice.** *Nephron.* 1998; 78(4): 440–52.
[PubMed Abstract](#) | [Publisher Full Text](#)
47. Papeta N, Zheng Z, Schon EA, et al.: **Prkdc participates in mitochondrial genome maintenance and prevents Adriamycin-induced nephropathy in mice.** *J Clin Invest.* 2010; 120(11): 4055–64.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
48. Zhang W, Li Q, Wang L, et al.: **Simvastatin ameliorates glomerulosclerosis in Adriamycin-induced-nephropathy rats.** *Pediatr Nephrol.* 2008; 23(12): 2185–94.
[PubMed Abstract](#) | [Publisher Full Text](#)
49. Liu HF, Guo LQ, Huang YY, et al.: **Thiazolidinedione attenuate proteinuria and glomerulosclerosis in Adriamycin-induced nephropathy rats via slit diaphragm protection.** *Nephrology (Carlton).* 2010; 15(1): 75–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
50. Wharram BL, Goyal M, Wiggins JE, et al.: **Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene.** *J Am Soc Nephrol.* 2005; 16(10): 2941–52.
[PubMed Abstract](#) | [Publisher Full Text](#)
51. Sato Y, Wharram BL, Lee SK, et al.: **Urine podocyte mRNAs mark progression of renal disease.** *J Am Soc Nephrol.* 2009; 20(5): 1041–52.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
52. Goldwich A, Steinkasserer A, Gessner A, et al.: **Impairment of podocyte function by diphtheria toxin—a new reversible proteinuria model in mice.** *Lab Invest.* 2012; 92(12): 1674–85.
[PubMed Abstract](#) | [Publisher Full Text](#)
53. Ichii O, Otsuka-Kanazawa S, Nakamura T, et al.: **Podocyte injury caused by indoxyl sulfate, a uremic toxin and aryl-hydrocarbon receptor ligand.** *PLoS One.* 2014; 9(9): e108448.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
54. Hughes AK, Stricklett PK, Schmid D, et al.: **Cytotoxic effect of Shiga toxin-1 on human glomerular epithelial cells.** *Kidney Int.* 2000; 57(6): 2350–9.
[PubMed Abstract](#) | [Publisher Full Text](#)

55. Morigi M, Buelli S, Zanchi C, *et al.*: **Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling.** *Am J Pathol.* 2006; **169**(6): 1965–75.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
56. Locatelli M, Buelli S, Pezzotta A, *et al.*: **Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement.** *J Am Soc Nephrol.* 2014; **25**(8): 1786–98.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
57. Reiser J, von Gersdorff G, Loos M, *et al.*: **Induction of B7-1 in podocytes is associated with nephrotic syndrome.** *J Clin Invest.* 2004; **113**(10): 1390–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
58. Sun Y, He L, Takemoto M, *et al.*: **Glomerular transcriptome changes associated with lipopolysaccharide-induced proteinuria.** *Am J Nephrol.* 2009; **29**(6): 558–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
59. Srivastava T, Sharma M, Yew KH, *et al.*: **LPS and PAN-induced podocyte injury in an *in vitro* model of minimal change disease: changes in TLR profile.** *J Cell Commun Signal.* 2013; **7**(1): 49–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
60. Wei C, Möller CC, Altintas MM, *et al.*: **Modification of kidney barrier function by the urokinase receptor.** *Nat Med.* 2008; **14**(1): 55–63.
[PubMed Abstract](#) | [Publisher Full Text](#)
61. **F** Sever S, Altintas MM, Nankoe SR, *et al.*: **Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease.** *J Clin Invest.* 2007; **117**(8): 2095–104.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
62. **F** Faul C, Donnelly M, Merscher-Gomez S, *et al.*: **The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A.** *Nat Med.* 2008; **14**(9): 931–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
63. Yaddanapudi S, Altintas MM, Kistler AD, *et al.*: **CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival.** *J Clin Invest.* 2011; **121**(10): 3965–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
64. Altintas MM, Moriwaki K, Wei C, *et al.*: **Reduction of proteinuria through podocyte alkalization.** *J Biol Chem.* 2014; **289**(25): 17454–67.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
65. **F** Shimada M, Ishimoto T, Lee PY, *et al.*: **Toll-like receptor 3 ligands induce CD80 expression in human podocytes via an NF- κ B-dependent pathway.** *Nephrol Dial Transplant.* 2012; **27**(1): 81–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
66. Cybulsky AV, Quigg RJ, Salant DJ: **Experimental membranous nephropathy redux.** *Am J Physiol Renal Physiol.* 2005; **289**(4): F660–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
67. Berger SP, Daha MR: **Complement in glomerular injury.** *Semin Immunopathol.* 2007; **29**(4): 375–84.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
68. Noris M, Remuzzi G: **Overview of complement activation and regulation.** *Semin Nephrol.* 2013; **33**(6): 479–92.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
69. Takano T, Elimam H, Cybulsky AV: **Complement-mediated cellular injury.** *Semin Nephrol.* 2013; **33**(6): 586–601.
[PubMed Abstract](#) | [Publisher Full Text](#)
70. Topham PS, Haydar SA, Kuphal R, *et al.*: **Complement-mediated injury reversibly disrupts glomerular epithelial cell actin microfilaments and focal adhesions.** *Kidney Int.* 1999; **55**(5): 1763–75.
[PubMed Abstract](#) | [Publisher Full Text](#)
71. Le Hir M, Haas C, Marino M, *et al.*: **Prevention of crescentic glomerulonephritis induced by anti-glomerular membrane antibody in tumor necrosis factor-deficient mice.** *Lab Invest.* 1998; **78**(12): 1625–31.
[PubMed Abstract](#)
72. Le Hir M, Keller C, Eschmann V, *et al.*: **Podocyte bridges between the tuft and Bowman's capsule: an early event in experimental crescentic glomerulonephritis.** *J Am Soc Nephrol.* 2001; **12**(10): 2060–71.
[PubMed Abstract](#)
73. Moeller MJ, Soofi A, Hartmann I, *et al.*: **Podocytes populate cellular crescents in a murine model of inflammatory glomerulonephritis.** *J Am Soc Nephrol.* 2004; **15**(1): 61–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
74. Wheeler J, Morley AR, Appleton DR: **Anti-glomerular basement membrane (GBM) glomerulonephritis in the mouse: development of disease and cell proliferation.** *J Exp Pathol (Oxford).* 1990; **71**(3): 411–22.
[PubMed Abstract](#) | [Free Full Text](#)
75. Shirato I, Hosser H, Kimura K, *et al.*: **The development of focal segmental glomerulosclerosis in masugi nephritis is based on progressive podocyte damage.** *Virchows Arch.* 1996; **429**(4–5): 255–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
76. Shirato I, Sakai T, Kimura K, *et al.*: **Cytoskeletal changes in podocytes associated with foot process effacement in Masugi nephritis.** *Am J Pathol.* 1996; **148**(4): 1283–96.
[PubMed Abstract](#) | [Free Full Text](#)
77. Ophascharoensuk V, Pippin JW, Gordon KL, *et al.*: **Role of intrinsic renal cells versus infiltrating cells in glomerular crescent formation.** *Kidney Int.* 1998; **54**(2): 416–25.
[PubMed Abstract](#) | [Publisher Full Text](#)
78. Kim YG, Alpers CE, Brugarolas J, *et al.*: **The cyclin kinase inhibitor p21^{CIP1/WAF1} limits glomerular epithelial cell proliferation in experimental glomerulonephritis.** *Kidney Int.* 1999; **55**(6): 2349–61.
[PubMed Abstract](#) | [Publisher Full Text](#)
79. Seiler MW, Venkatachalam MA, Cotran RS: **Glomerular epithelium: structural alterations induced by polycations.** *Science.* 1975; **189**(4200): 390–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
80. Kerjaschki D: **Polycation-induced dislocation of slit diaphragms and formation of cell junctions in rat kidney glomeruli: the effects of low temperature, divalent cations, colchicine, and cytochalasin B.** *Lab Invest.* 1978; **39**(5): 430–40.
[PubMed Abstract](#)
81. **F** George B, Verma R, Soofi AA, *et al.*: **Crk1/2-dependent signaling is necessary for podocyte foot process spreading in mouse models of glomerular disease.** *J Clin Invest.* 2012; **122**(2): 674–92.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
82. Reiser J, Pixley FJ, Hug A, *et al.*: **Regulation of mouse podocyte process dynamics by protein tyrosine phosphatases rapid communication.** *Kidney Int.* 2000; **57**(5): 2035–42.
[PubMed Abstract](#) | [Publisher Full Text](#)
83. Rüdiger F, Greger R, Nitschke R, *et al.*: **Polycations induce calcium signaling in glomerular podocytes.** *Kidney Int.* 1999; **56**(5): 1700–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
84. **F** Schaldecker T, Kim S, Tarabnis C, *et al.*: **Inhibition of the TRPC5 ion channel protects the kidney filter.** *J Clin Invest.* 2013; **123**(12): 5298–309.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
85. Seiler MW, Rennke HG, Venkatachalam MA, *et al.*: **Pathogenesis of polycation-induced alterations (“fusion”) of glomerular epithelium.** *Lab Invest.* 1977; **36**(1): 48–61.
[PubMed Abstract](#)
86. **F** Verma R, Kovari I, Soofi A, *et al.*: **Nephrin ectodomain engagement results in Src kinase activation, nephrin phosphorylation, Nck recruitment, and actin polymerization.** *J Clin Invest.* 2006; **116**(5): 1346–59.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
87. Daniels BS: **Increased albumin permeability *in vitro* following alterations of glomerular charge is mediated by the cells of the filtration barrier.** *J Lab Clin Med.* 1994; **124**(2): 224–30.
[PubMed Abstract](#)
88. Andrews PM: **Glomerular epithelial alterations resulting from sialic acid surface coat removal.** *Kidney Int.* 1979; **15**(4): 376–85.
[PubMed Abstract](#) | [Publisher Full Text](#)
89. Galeano B, Klootwijk R, Manoli I, *et al.*: **Mutation in the key enzyme of sialic acid biosynthesis causes severe glomerular proteinuria and is rescued by N-acetylmannosamine.** *J Clin Invest.* 2007; **117**(6): 1585–94.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
90. Asanuma K, Kim K, Oh J, *et al.*: **Synaptopodin regulates the actin-bundling activity of alpha-actinin in an isoform-specific manner.** *J Clin Invest.* 2005; **115**(5): 1188–98.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
91. **F** Asanuma K, Yanagida-Asanuma E, Faul C, *et al.*: **Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signalling.** *Nat Cell Biol.* 2006; **8**(5): 485–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
92. **F** Huber TB, Kwok C, Wu H, *et al.*: **Bigenic mouse models of focal segmental glomerulosclerosis involving pairwise interaction of CD2AP, Fyn, and synaptopodin.** *J Clin Invest.* 2006; **116**(5): 1337–45.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
93. **F** Kaplan JM, Kim SH, North KN, *et al.*: **Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis.** *Nat Genet.* 2000; **24**(3): 251–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
94. **F** Kos CH, Le TC, Sinha S, *et al.*: **Mice deficient in alpha-actinin-4 have severe glomerular disease.** *J Clin Invest.* 2003; **111**(11): 1683–90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
95. **F** Michaud J, Lemieux LI, Dubé M, *et al.*: **Focal and segmental glomerulosclerosis in mice with podocyte-specific expression of mutant alpha-actinin-4.** *J Am Soc Nephrol.* 2003; **14**(5): 1200–11.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
96. Michaud JL, Chaisson KM, Parks RJ, *et al.*: **FSGS-associated alpha-actinin-4 (K256E) impairs cytoskeletal dynamics in podocytes.** *Kidney Int.* 2006; **70**(6): 1054–61.
[PubMed Abstract](#) | [Publisher Full Text](#)
97. **F** Gu C, Yaddanapudi S, Weins A, *et al.*: **Direct dynamin-actin interactions regulate the actin cytoskeleton.** *EMBO J.* 2010; **29**(21): 3593–606.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**

98. Soda K, Balkin DM, Ferguson SM, *et al.*: **Role of dynamin, synaptojanin, and endophilin in podocyte foot processes.** *J Clin Invest.* 2012; 122(12): 4401–11. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
99. Ashraf S, Gee HY, Woerner S, *et al.*: **ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ₁₀ biosynthesis disruption.** *J Clin Invest.* 2013; 123(12): 5179–89. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
100. Gbadegesin RA, Hall G, Adeyemo A, *et al.*: **Mutations in the gene that encodes the F-actin binding protein anillin cause FSGS.** *J Am Soc Nephrol.* 2014; 25(9): 1991–2002. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
101. Lan X, Jhaveri A, Cheng K, *et al.*: **APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability.** *Am J Physiol Renal Physiol.* 2014; 307(3): F326–36. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
102. **F** Akilesh S, Suleiman H, Yu H, *et al.*: **Arhgap24 inactivates Rac1 in mouse podocytes, and a mutant form is associated with familial focal segmental glomerulosclerosis.** *J Clin Invest.* 2011; 121(10): 4127–37. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
103. Togawa A, Miyoshi J, Ishizaki H, *et al.*: **Progressive impairment of kidneys and reproductive organs in mice lacking Rho GDIalpha.** *Oncogene.* 1999; 18(39): 5373–80. [PubMed Abstract](#) | [Publisher Full Text](#)
104. Gee HY, Saisawat P, Ashraf S, *et al.*: **ARHGDI mutations cause nephrotic syndrome via defective RHO GTPase signaling.** *J Clin Invest.* 2013; 123(8): 3243–53. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
105. **F** Gupta IR, Baldwin C, Auguste D, *et al.*: **ARHGDI: a novel gene implicated in nephrotic syndrome.** *J Med Genet.* 2013; 50(5): 330–8. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
106. **F** Hasegawa K, Wakino S, Simic P, *et al.*: **Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes.** *Nat Med.* 2013; 19(11): 1496–504. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
107. Wegner B, Al-Momany A, Kulak SC, *et al.*: **CLIC5A, a component of the ezrin-podocalyxin complex in glomeruli, is a determinant of podocyte integrity.** *Am J Physiol Renal Physiol.* 2010; 298(6): F1492–503. [PubMed Abstract](#) | [Publisher Full Text](#)
108. Garg P, Verma R, Cook L, *et al.*: **Actin-depolymerizing factor cofilin-1 is necessary in maintaining mature podocyte architecture.** *J Biol Chem.* 2010; 285(29): 22676–88. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
109. Ashworth S, Teng B, Kaufeld J, *et al.*: **Cofilin-1 inactivation leads to proteinuria—studies in zebrafish, mice and humans.** *PLoS One.* 2010; 5(9): e12626. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
110. Wasik AA, Koskelainen S, Hyvönen ME, *et al.*: **Ezrin is down-regulated in diabetic kidney glomeruli and regulates actin reorganization and glucose uptake via GLUT1 in cultured podocytes.** *Am J Pathol.* 2014; 184(6): 1727–39. [PubMed Abstract](#) | [Publisher Full Text](#)
111. **F** Brown EJ, Schlöndorff JS, Becker DJ, *et al.*: **Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis.** *Nat Genet.* 2010; 42(1): 72–6. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
112. Boyer O, Benoit G, Gribouval O, *et al.*: **Mutations in INF2 are a major cause of autosomal dominant focal segmental glomerulosclerosis.** *J Am Soc Nephrol.* 2011; 22(2): 239–45. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
113. Barua M, Brown EJ, Charoonratana VT, *et al.*: **Mutations in the INF2 gene account for a significant proportion of familial but not sporadic focal and segmental glomerulosclerosis.** *Kidney Int.* 2013; 83(2): 316–22. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
114. Sun H, Al-Romaih KI, MacRae CA, *et al.*: **Human Kidney Disease-causing INF2 Mutations Perturb Rho/Dia Signaling in the Glomerulus.** *EBioMedicine.* 2014; 1(2–3): 107–15. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
115. **F** Gee HY, Zhang F, Ashraf S, *et al.*: **KANK deficiency leads to podocyte dysfunction and nephrotic syndrome.** *J Clin Invest.* 2015; 125(6): 2375–84. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
116. Schell C, Baumhagl L, Salou S, *et al.*: **N-wasp is required for stabilization of podocyte foot processes.** *J Am Soc Nephrol.* 2013; 24(5): 713–21. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
117. Harris DP, Vogel P, Wims M, *et al.*: **Requirement for class II phosphoinositide 3-kinase C2alpha in maintenance of glomerular structure and function.** *Mol Cell Biol.* 2011; 31(1): 63–80. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
118. **F** Hinkes B, Wiggins RC, Gbadegesin R, *et al.*: **Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible.** *Nat Genet.* 2006; 38(12): 1397–405. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
119. Blattner SM, Hodgins JB, Nishio M, *et al.*: **Divergent functions of the Rho GTPases Rac1 and Cdc42 in podocyte injury.** *Kidney Int.* 2013; 84(5): 920–30. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
120. Ishizaka M, Gohda T, Takagi M, *et al.*: **Podocyte-specific deletion of Rac1 leads to aggravation of renal injury in STZ-induced diabetic mice.** *Biochem Biophys Res Commun.* 2015; 467(3): 549–55. [PubMed Abstract](#) | [Publisher Full Text](#)
121. Lal MA, Andersson AC, Katayama K, *et al.*: **Rhopillin-1 is a key regulator of the podocyte cytoskeleton and is essential for glomerular filtration.** *J Am Soc Nephrol.* 2015; 26(3): 647–62. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
122. Perisic L, Rodriguez PQ, Hultenby K, *et al.*: **Schp1 is a novel podocyte foot process protein that mediates actin cytoskeleton rearrangements and forms a complex with Nherf2 and ezrin.** *PLoS One.* 2015; 10(3): e0122067. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
123. Kim JH, Mukherjee A, Madhavan SM, *et al.*: **WT1-interacting protein (Wtip) regulates podocyte phenotype by cell-cell and cell-matrix contact reorganization.** *Am J Physiol Renal Physiol.* 2012; 302(1): F103–15. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
124. **F** Kestilä M, Lenkkeri U, Männikkö M, *et al.*: **Positionally cloned gene for a novel glomerular protein—nephrin—is mutated in congenital nephrotic syndrome.** *Mol Cell.* 1998; 1(4): 575–82. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
125. **F** Putaala H, Soininen R, Kilpeläinen P, *et al.*: **The murine nephrin gene is specifically expressed in kidney, brain and pancreas: inactivation of the gene leads to massive proteinuria and neonatal death.** *Hum Mol Genet.* 2001; 10(1): 1–8. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
126. Garg P, Verma R, Nihalani D, *et al.*: **Neph1 cooperates with nephrin to transduce a signal that induces actin polymerization.** *Mol Cell Biol.* 2007; 27(24): 8698–712. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
127. **F** Boute N, Gribouval O, Roselli S, *et al.*: **NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome.** *Nat Genet.* 2000; 24(4): 349–54. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
128. **F** Huber TB, Simons M, Hartleben B, *et al.*: **Molecular basis of the functional podocin-nephrin complex: mutations in the NPHS2 gene disrupt nephrin targeting to lipid raft microdomains.** *Hum Mol Genet.* 2003; 12(24): 3397–405. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
129. **F** Roselli S, Heidet L, Sich M, *et al.*: **Early glomerular filtration defect and severe renal disease in podocin-deficient mice.** *Mol Cell Biol.* 2004; 24(2): 550–60. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
130. **F** Shih NY, Li J, Karpitskii V, *et al.*: **Congenital nephrotic syndrome in mice lacking CD2-associated protein.** *Science.* 1999; 286(5438): 312–5. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
131. **F** Kim JM, Wu H, Green G, *et al.*: **CD2-associated protein haploinsufficiency is linked to glomerular disease susceptibility.** *Science.* 2003; 300(5623): 1298–300. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
132. **F** Jones N, Blasutig IM, Eremina V, *et al.*: **Nck adaptor proteins link nephrin to the actin cytoskeleton of kidney podocytes.** *Nature.* 2006; 440(7085): 818–23. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
133. Jones N, New LA, Fortino MA, *et al.*: **Nck proteins maintain the adult glomerular filtration barrier.** *J Am Soc Nephrol.* 2009; 20(7): 1533–43. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
134. Hofstra JM, Lainez S, van Kuijk WH, *et al.*: **New TRPC6 gain-of-function mutation in a non-consanguineous Dutch family with late-onset focal segmental glomerulosclerosis.** *Nephrol Dial Transplant.* 2013; 28(7): 1830–8. [PubMed Abstract](#) | [Publisher Full Text](#)
135. **F** Reiser J, Polu KR, Möller CC, *et al.*: **TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function.** *Nat Genet.* 2005; 37(7): 739–44. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
136. **F** Winn MP, Conlon PJ, Lynn KL, *et al.*: **A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis.** *Science.* 2005; 308(5729): 1801–4. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
137. Möller CC, Wei C, Altintas MM, *et al.*: **Induction of TRPC6 channel in acquired forms of proteinuric kidney disease.** *J Am Soc Nephrol.* 2007; 18(1): 29–36. [PubMed Abstract](#) | [Publisher Full Text](#)
138. Heeringa SF, Möller CC, Du J, *et al.*: **A novel TRPC6 mutation that causes childhood FSGS.** *PLoS One.* 2009; 4(11): e7771. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
139. Schlöndorff J, Del Camino D, Carrasquillo R, *et al.*: **TRPC6 mutations associated with focal segmental glomerulosclerosis cause constitutive activation of NFAT-dependent transcription.** *Am J Physiol Cell Physiol.* 2009; 296(3): C558–69. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
140. Chiliza D, Krishna S, Schumacher VA, *et al.*: **Gain-of-function mutations in transient receptor potential C6 (TRPC6) activate extracellular signal-regulated kinases 1/2 (ERK1/2).** *J Biol Chem.* 2013; 288(25): 18407–20. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

141. Kistler AD, Singh G, Altintas MM, *et al.*: **Transient receptor potential channel 6 (TRPC6) protects podocytes during complement-mediated glomerular disease.** *J Biol Chem.* 2013; **288**(51): 36598–609.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
142. Nyström J, Hultenby K, Ek S, *et al.*: **CRIM1 is localized to the podocyte filtration slit diaphragm of the adult human kidney.** *Nephrol Dial Transplant.* 2009; **24**(7): 2038–44.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
143. Ciani L, Patel A, Allen ND, *et al.*: **Mice lacking the giant protocadherin mFAT1 exhibit renal slit junction abnormalities and a partially penetrant cyclopia and anophthalmia phenotype.** *Mol Cell Biol.* 2003; **23**(10): 3575–82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
144. Yu CC, Yen TS, Lowell CA, *et al.*: **Lupus-like kidney disease in mice deficient in the Src family tyrosine kinases Lyn and Fyn.** *Curr Biol.* 2001; **11**(1): 34–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
145. Verma R, Wharram B, Kovari I, *et al.*: **Fyn binds to and phosphorylates the kidney slit diaphragm component Nephrin.** *J Biol Chem.* 2003; **278**(23): 20716–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
146. Rigothier C, Auguste P, Welsh GI, *et al.*: **IQGAP1 interacts with components of the slit diaphragm complex in podocytes and is involved in podocyte migration and permeability in vitro.** *PLoS One.* 2012; **7**(5): e37695.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
147. Liu Y, Liang W, Yang Y, *et al.*: **IQGAP1 regulates actin cytoskeleton organization in podocytes through interaction with nephrin.** *Cell Signal.* 2015; **27**(4): 867–77.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
148. Balbas MD, Burgess MR, Murali R, *et al.*: **MAGI-2 scaffold protein is critical for kidney barrier function.** *Proc Natl Acad Sci U S A.* 2014; **111**(41): 14876–81.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
149. Arif E, Wagner MC, Johnstone DB, *et al.*: **Motor protein Myo1c is a podocyte protein that facilitates the transport of slit diaphragm protein Nephrin to the podocyte membrane.** *Mol Cell Biol.* 2011; **31**(10): 2134–50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
150. Krendel M, Kim SV, Willinger T, *et al.*: **Disruption of Myosin 1e promotes podocyte injury.** *J Am Soc Nephrol.* 2009; **20**(1): 86–94.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
151. Mele C, Iatropoulos P, Donadelli R, *et al.*: **MYO1E mutations and childhood familial focal segmental glomerulosclerosis.** *N Engl J Med.* 2011; **365**(4): 295–306.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
152. Sanna-Cherchi S, Burgess KE, Nees SN, *et al.*: **Exome sequencing identified MYO1E and NEIL1 as candidate genes for human autosomal recessive steroid-resistant nephrotic syndrome.** *Kidney Int.* 2011; **80**(4): 389–96.
[PubMed Abstract](#) | [Publisher Full Text](#)
153. Chase SE, Encina CV, Stolzenburg LR, *et al.*: **Podocyte-specific knockout of myosin 1e disrupts glomerular filtration.** *Am J Physiol Renal Physiol.* 2012; **303**(7): F1099–106.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
154. Donoviel DB, Freed DD, Vogel H, *et al.*: **Proteinuria and perinatal lethality in mice lacking NEPH1, a novel protein with homology to NEPHRIN.** *Mol Cell Biol.* 2001; **21**(14): 4829–36.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
155. Itoh M, Nakadate K, Horibata Y, *et al.*: **The structural and functional organization of the podocyte filtration slits is regulated by Tjp1/ZO-1.** *PLoS One.* 2014; **9**(9): e106621.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
156. Doyonnas R, Kershaw DB, Duhme C, *et al.*: **Anuria, omphalocele, and perinatal lethality in mice lacking the CD34-related protein podocalyxin.** *J Exp Med.* 2001; **194**(1): 13–27.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
157. Fukasawa H, Obayashi H, Schmieder S, *et al.*: **Phosphorylation of podocalyxin (Ser415) Prevents RhoA and ezrin activation and disrupts its interaction with the actin cytoskeleton.** *Am J Pathol.* 2011; **179**(5): 2254–65.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
158. Wharram BL, Goyal M, Gillespie PJ, *et al.*: **Altered podocyte structure in GLEPP1 (Ptpn) deficient mice associated with hypertension and low glomerular filtration rate.** *J Clin Invest.* 2000; **106**(10): 1281–90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
159. Ozaltin F, Ibsirlioglu T, Taskiran EZ, *et al.*: **Disruption of PTPRO causes childhood-onset nephrotic syndrome.** *Am J Hum Genet.* 2011; **89**(1): 139–47.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
160. Scott RP, Hawley SP, Ruston J, *et al.*: **Podocyte-specific loss of Cdc42 leads to congenital nephropathy.** *J Am Soc Nephrol.* 2012; **23**(7): 1149–54.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
161. Hirose T, Satoh D, Kurihara H, *et al.*: **An essential role of the universal polarity protein, aPKCλ, on the maintenance of podocyte slit diaphragms.** *PLoS One.* 2009; **4**(1): e4194.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
162. Huber TB, Hartleben B, Winkelmann K, *et al.*: **Loss of podocyte aPKCλ/δ causes polarity defects and nephrotic syndrome.** *J Am Soc Nephrol.* 2009; **20**(4): 798–806.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
163. Satoh D, Hirose T, Harita Y, *et al.*: **aPKCλ maintains the integrity of the glomerular slit diaphragm through trafficking of nephrin to the cell surface.** *J Biochem.* 2014; **156**(2): 115–28.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
164. Babayeva S, Zilber Y, Torban E: **Planar cell polarity pathway regulates actin rearrangement, cell shape, motility, and nephrin distribution in podocytes.** *Am J Physiol Renal Physiol.* 2011; **300**(2): F549–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
165. Babayeva S, Rocque B, Aoudjit L, *et al.*: **Planar cell polarity pathway regulates nephrin endocytosis in developing podocytes.** *J Biol Chem.* 2013; **288**(33): 24035–48.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
166. Rocque BL, Babayeva S, Li J, *et al.*: **Deficiency of the planar cell polarity protein Vangl2 in podocytes affects glomerular morphogenesis and increases susceptibility to injury.** *J Am Soc Nephrol.* 2015; **26**(3): 576–86.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
167. Kreidberg JA, Donovan MJ, Goldstein SL, *et al.*: **Alpha 3 beta 1 integrin has a crucial role in kidney and lung organogenesis.** *Development.* 1996; **122**(11): 3537–47.
[PubMed Abstract](#)
168. Kanasaki K, Kanda Y, Palmsten K, *et al.*: **Integrin beta1-mediated matrix assembly and signaling are critical for the normal development and function of the kidney glomerulus.** *Dev Biol.* 2008; **313**(2): 584–93.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
169. Pozzi A, Jarad G, Moekel GW, *et al.*: **Beta1 integrin expression by podocytes is required to maintain glomerular structural integrity.** *Dev Biol.* 2008; **316**(2): 288–301.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
170. Kambham N, Tanji N, Seigle RL, *et al.*: **Congenital focal segmental glomerulosclerosis associated with beta4 integrin mutation and epidermolysis bullosa.** *Am J Kidney Dis.* 2000; **36**(1): 190–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
171. Blumenthal A, Giebel J, Warsow G, *et al.*: **Mechanical stress enhances CD9 expression in cultured podocytes.** *Am J Physiol Renal Physiol.* 2015; **308**(6): F602–13.
[PubMed Abstract](#) | [Publisher Full Text](#)
172. Karamatic Crew V, Burton N, Kagan A, *et al.*: **CD151, the first member of the tetraspanin (TM4) superfamily detected on erythrocytes, is essential for the correct assembly of human basement membranes in kidney and skin.** *Blood.* 2004; **104**(8): 2217–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
173. Sachs N, Kreft M, van den Bergh Weerman MA, *et al.*: **Kidney failure in mice lacking the tetraspanin CD151.** *J Cell Biol.* 2006; **175**(1): 33–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
174. Baleato RM, Guthrie PL, Gubler MC, *et al.*: **Deletion of CD151 results in a strain-dependent glomerular disease due to severe alterations of the glomerular basement membrane.** *Am J Pathol.* 2008; **173**(4): 927–37.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
175. Blumenthal A, Giebel J, Ummanni R, *et al.*: **Morphology and migration of podocytes are affected by CD151 levels.** *Am J Physiol Renal Physiol.* 2012; **302**(10): F1265–77.
[PubMed Abstract](#) | [Publisher Full Text](#)
176. Hudson BG, Tryggvason K, Sundaramoorthy M, *et al.*: **Alport's syndrome, Goodpasture's syndrome, and type IV collagen.** *N Engl J Med.* 2003; **348**(25): 2543–56.
[PubMed Abstract](#) | [Publisher Full Text](#)
177. Hudson BG: **The molecular basis of Goodpasture and Alport syndromes: beacons for the discovery of the collagen IV family.** *J Am Soc Nephrol.* 2004; **15**(10): 2514–27.
[PubMed Abstract](#) | [Publisher Full Text](#)
178. Gubler MC: **Inherited diseases of the glomerular basement membrane.** *Nat Clin Pract Nephrol.* 2008; **4**(1): 24–37.
[PubMed Abstract](#) | [Publisher Full Text](#)
179. Gross O, Beirowski B, Harvey SJ, *et al.*: **DDR1-deficient mice show localized subepithelial GBM thickening with focal loss of slit diaphragms and proteinuria.** *Kidney Int.* 2004; **66**(1): 102–11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
180. Okamoto K, Tokunaga K, Doi K, *et al.*: **Common variation in GPC5 is associated with acquired nephrotic syndrome.** *Nat Genet.* 2011; **43**(5): 459–63.
[PubMed Abstract](#) | [Publisher Full Text](#)
181. Dai C, Stolz DB, Bastacky SI, *et al.*: **Essential role of integrin-linked kinase in podocyte biology: Bridging the integrin and slit diaphragm signaling.** *J Am Soc Nephrol.* 2006; **17**(8): 2164–75.
[PubMed Abstract](#) | [Publisher Full Text](#)
182. El-Aouni C, Herbach N, Blattner SM, *et al.*: **Podocyte-specific deletion of integrin-linked kinase results in severe glomerular basement membrane alterations and progressive glomerulosclerosis.** *J Am Soc Nephrol.* 2006; **17**(5): 1334–44.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
183. Noakes PG, Miner JH, Gautam M, *et al.*: **The renal glomerulus of mice lacking s-laminin/laminin beta 2: nephrosis despite molecular compensation by laminin beta 1.** *Nat Genet.* 1995; **10**(4): 400–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
184. Jarad G, Cunningham J, Shaw AS, *et al.*: **Proteinuria precedes podocyte abnormalities in *Lamb2*^{-/-} mice, implicating the glomerular basement membrane as an albumin barrier.** *J Clin Invest.* 2006; **116**(8): 2272–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

185. Chen YM, Kikkawa Y, Miner JH: **A missense *LAMB2* mutation causes congenital nephrotic syndrome by impairing laminin secretion.** *J Am Soc Nephrol.* 2011; 22(5): 849–58.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
186. **F** Chen YM, Zhou Y, Go G, *et al.*: **Laminin $\beta 2$ gene missense mutation produces endoplasmic reticulum stress in podocytes.** *J Am Soc Nephrol.* 2013; 24(8): 1223–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
187. **F** Sugar T, Wassenhove-McCarthy DJ, Esko JD, *et al.*: **Podocyte-specific deletion of *NDST1*, a key enzyme in the sulfation of heparan sulfate glycosaminoglycans, leads to abnormalities in podocyte organization *in vivo*.** *Kidney Int.* 2014; 85(2): 307–18.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
188. Potla U, Ni J, Vadaparampil J, *et al.*: **Podocyte-specific *RAP1GAP* expression contributes to focal segmental glomerulosclerosis-associated glomerular injury.** *J Clin Invest.* 2014; 124(4): 1757–69.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
189. Tian X, Kim JJ, Monkley SM, *et al.*: **Podocyte-associated *talin1* is critical for glomerular filtration barrier maintenance.** *J Clin Invest.* 2014; 124(3): 1098–113.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
190. Berkovic SF, Dibbens LM, Oshlack A, *et al.*: **Array-based gene discovery with three unrelated subjects shows *SCARB2/LIMP-2* deficiency causes myoclonus epilepsy and glomerulosclerosis.** *Am J Hum Genet.* 2008; 82(3): 673–84.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
191. Diomedes-Camassei F, Di Giandomenico S, Santorelli FM, *et al.*: ***COQ2* nephropathy: a newly described inherited mitochondriopathy with primary renal involvement.** *J Am Soc Nephrol.* 2007; 18(10): 2773–80.
[PubMed Abstract](#) | [Publisher Full Text](#)
192. Heeringa SF, Chernin G, Chaki M, *et al.*: ***COQ6* mutations in human patients produce nephrotic syndrome with sensorineural deafness.** *J Clin Invest.* 2011; 121(5): 2013–24.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
193. Casalena G, Krick S, Daehn I, *et al.*: ***Mpv17* in mitochondria protects podocytes against mitochondrial dysfunction and apoptosis *in vivo* and *in vitro*.** *Am J Physiol Renal Physiol.* 2014; 306(11): F1372–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
194. Löwik MM, Hol FA, Steenbergen EJ, *et al.*: **Mitochondrial *tRNA*^{Leu(UUR)} mutation in a patient with steroid-resistant nephrotic syndrome and focal segmental glomerulosclerosis.** *Nephrol Dial Transplant.* 2005; 20(2): 336–41.
[PubMed Abstract](#) | [Publisher Full Text](#)
195. Ising C, Koehler S, Brähler S, *et al.*: **Inhibition of insulin/IGF-1 receptor signaling protects from mitochondria-mediated kidney failure.** *EMBO Mol Med.* 2015; 7(3): 275–87.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
196. **F** Hartleben B, Gödel M, Meyer-Schwesinger C, *et al.*: **Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice.** *J Clin Invest.* 2010; 120(4): 1084–96.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
197. **F** Cinà DP, Onay T, Paltoo A, *et al.*: **Inhibition of *MTOR* disrupts autophagic flux in podocytes.** *J Am Soc Nephrol.* 2012; 23(3): 412–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
198. **F** Riediger F, Quack I, Qadri F, *et al.*: **Prorenin receptor is essential for podocyte autophagy and survival.** *J Am Soc Nephrol.* 2011; 22(12): 2193–202.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
199. Oshima Y, Kinouchi K, Ichihara A, *et al.*: **Prorenin receptor is essential for normal podocyte structure and function.** *J Am Soc Nephrol.* 2011; 22(12): 2203–12.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
200. Li C, Siragy HM: **(Pro)renin receptor regulates autophagy and apoptosis in podocytes exposed to high glucose.** *Am J Physiol Endocrinol Metab.* 2015; 309(3): E302–10.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
201. Chen J, Chen MX, Fogo AB, *et al.*: ***mVps34* deletion in podocytes causes glomerulosclerosis by disrupting intracellular vesicle trafficking.** *J Am Soc Nephrol.* 2013; 24(2): 198–207.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
202. Bechtel W, Helmstädter M, Balica J, *et al.*: ***Vps34* deficiency reveals the importance of endocytosis for podocyte homeostasis.** *J Am Soc Nephrol.* 2013; 24(5): 727–43.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
203. **F** Weins A, Wong JS, Basgen JM, *et al.*: **Dendrin ablation prolongs life span by delaying kidney failure.** *Am J Pathol.* 2015; 185(8): 2143–57.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
204. Li X, Zhang X, Li X, *et al.*: **The role of survivin in podocyte injury induced by puromycin aminonucleoside.** *Int J Mol Sci.* 2014; 15(4): 6657–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
205. Campbell KN, Wong JS, Gupta R, *et al.*: **Yes-associated protein (*YAP*) promotes cell survival by inhibiting proapoptotic dendrin signaling.** *J Biol Chem.* 2013; 288(24): 17057–62.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
206. Schwartzman M, Reginensi A, Wong JS, *et al.*: **Podocyte-Specific Deletion of Yes-Associated Protein Causes FSGS and Progressive Renal Failure.** *J Am Soc Nephrol.* 2016; 27(1): 216–26.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
207. **F** Eremina V, Sood M, Haigh J, *et al.*: **Glomerular-specific alterations of *VEGF-A* expression lead to distinct congenital and acquired renal diseases.** *J Clin Invest.* 2003; 111(5): 707–16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
208. Eremina V, Cui S, Gerber H, *et al.*: **Vascular endothelial growth factor *a* signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival.** *J Am Soc Nephrol.* 2006; 17(3): 724–35.
[PubMed Abstract](#) | [Publisher Full Text](#)
209. Kato H, Gruenwald A, Suh JH, *et al.*: ***Wnt*/ β -catenin pathway in podocytes integrates cell adhesion, differentiation, and survival.** *J Biol Chem.* 2011; 286(29): 26003–15.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
210. **F** Niranjan T, Bielez B, Gruenwald A, *et al.*: **The Notch pathway in podocytes plays a role in the development of glomerular disease.** *Nat Med.* 2008; 14(3): 290–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
211. Kretzler M, Teixeira VP, Unschuld PG, *et al.*: **Integrin-linked kinase as a candidate downstream effector in proteinuria.** *FASEB J.* 2001; 15(10): 1843–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
212. Teixeira Vde P, Blattner SM, Li M, *et al.*: **Functional consequences of integrin-linked kinase activation in podocyte damage.** *Kidney Int.* 2005; 67(2): 514–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
213. Kang YS, Li Y, Dai C, *et al.*: **Inhibition of integrin-linked kinase blocks podocyte epithelial-mesenchymal transition and ameliorates proteinuria.** *Kidney Int.* 2010; 78(4): 363–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
214. He JC, Husain M, Sunamoto M, *et al.*: **Nef stimulates proliferation of glomerular podocytes through activation of *Src*-dependent *Stat3* and *MAPK1.2* pathways.** *J Clin Invest.* 2004; 114(5): 643–51.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
215. Zuo Y, Matsusaka T, Zhong J, *et al.*: ***HIV-1* genes *vpr* and *nef* synergistically damage podocytes, leading to glomerulosclerosis.** *J Am Soc Nephrol.* 2006; 17(10): 2832–43.
[PubMed Abstract](#) | [Publisher Full Text](#)
216. Waters AM, Wu MY, Onay T, *et al.*: **Ectopic notch activation in developing podocytes causes glomerulosclerosis.** *J Am Soc Nephrol.* 2008; 19(6): 1139–57.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
217. Wasik AA, Polianskyte-Prause Z, Dong MQ, *et al.*: **Septin 7 forms a complex with *CD2AP* and nephrin and regulates glucose transporter trafficking.** *Mol Biol Cell.* 2012; 23(17): 3370–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
218. Schiffer M, Bitzer M, Roberts IS, *et al.*: **Apoptosis in podocytes induced by *TGF-beta* and *Smad7*.** *J Clin Invest.* 2001; 108(8): 807–16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
219. **F** Inoki K, Mori H, Wang J, *et al.*: ***mTORC1* activation in podocytes is a critical step in the development of diabetic nephropathy in mice.** *J Clin Invest.* 2011; 121(6): 2181–96.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
220. Dai C, Stolz DB, Kiss LP, *et al.*: ***Wnt*/ β -catenin signaling promotes podocyte dysfunction and albuminuria.** *J Am Soc Nephrol.* 2009; 20(9): 1997–2008.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
221. **F** Canaud G, Bienaimé F, Viau A, *et al.*: ***AKT2* is essential to maintain podocyte viability and function during chronic kidney disease.** *Nat Med.* 2013; 19(10): 1288–96.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
222. Yang Y, Guo L, Blattner SM, *et al.*: **Formation and phosphorylation of the *PINCH-1*-integrin linked kinase- α -parvin complex are important for regulation of renal glomerular podocyte adhesion, architecture, and survival.** *J Am Soc Nephrol.* 2005; 16(7): 1966–76.
[PubMed Abstract](#) | [Publisher Full Text](#)
223. Rüster C, Franke S, Wenzel U, *et al.*: **Podocytes of *AT2* receptor knockout mice are protected from angiotensin II-mediated *RAGE* induction.** *Am J Nephrol.* 2011; 34(4): 309–17.
[PubMed Abstract](#) | [Publisher Full Text](#)
224. Heikkilä E, Juhila J, Lassila M, *et al.*: **β -Catenin mediates adriamycin-induced albuminuria and podocyte injury in adult mouse kidneys.** *Nephrol Dial Transplant.* 2010; 25(8): 2437–46.
[PubMed Abstract](#) | [Publisher Full Text](#)
225. Jiang L, Xu L, Song Y, *et al.*: **Calmodulin-dependent protein kinase II/cAMP response element-binding protein/*Wnt*/ β -catenin signaling cascade regulates angiotensin II-induced podocyte injury and albuminuria.** *J Biol Chem.* 2013; 288(32): 23368–79.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
226. Lu T, He JC, Wang ZH, *et al.*: ***HIV-1* Nef disrupts the podocyte actin cytoskeleton by interacting with diaphanous interacting protein.** *J Biol Chem.* 2008; 283(13): 8173–82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
227. **F** Welsh GI, Hale LJ, Eremina V, *et al.*: **Insulin signaling to the glomerular podocyte is critical for normal kidney function.** *Cell Metab.* 2010; 12(4): 329–40.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
228. Hale LJ, Welsh GI, Perks CM, *et al.*: **Insulin-like growth factor-II is produced by, signals to and is an important survival factor for the mature podocyte in man and mouse.** *J Pathol.* 2013; 230(1): 95–106.
[PubMed Abstract](#) | [Publisher Full Text](#)

229. **F** Hale LJ, Hurcombe J, Lay A, *et al.*: **Insulin directly stimulates VEGF-A production in the glomerular podocyte.** *Am J Physiol Renal Physiol.* 2013; 305(2): F182–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
230. Brähler S, Ising C, Hagmann H, *et al.*: **Intrinsic proinflammatory signaling in podocytes contributes to podocyte damage and prolonged proteinuria.** *Am J Physiol Renal Physiol.* 2012; 303(10): F1473–85.
[PubMed Abstract](#) | [Publisher Full Text](#)
231. Brähler S, Ising C, Barrera Aranda B, *et al.*: **The NF- κ B essential modulator (NEMO) controls podocyte cytoskeletal dynamics independently of NF- κ B.** *Am J Physiol Renal Physiol.* 2015; 309(7): F617–26.
[PubMed Abstract](#) | [Publisher Full Text](#)
232. Lin CL, Wang FS, Hsu YC, *et al.*: **Modulation of notch-1 signaling alleviates vascular endothelial growth factor-mediated diabetic nephropathy.** *Diabetes.* 2010; 59(8): 1915–25.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
233. El Machhour F, Keuylian Z, Kavvasas P, *et al.*: **Activation of Notch3 in Glomeruli Promotes the Development of Rapidly Progressive Renal Disease.** *J Am Soc Nephrol.* 2015; 26(7): 1561–75.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
234. Saurus P, Kuusela S, Lehtonen E, *et al.*: **Podocyte apoptosis is prevented by blocking the Toll-like receptor pathway.** *Cell Death Dis.* 2015; 6: e1752.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
235. Gödel M, Hartleben B, Herbach N, *et al.*: **Role of mTOR in podocyte function and diabetic nephropathy in humans and mice.** *J Clin Invest.* 2011; 121(6): 2197–209.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
236. Hyvönen ME, Saurus P, Wasik A, *et al.*: **Lipid phosphatase SHIP2 downregulates insulin signalling in podocytes.** *Mol Cell Endocrinol.* 2010; 328(1–2): 70–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
237. Das R, Xu S, Quan X, *et al.*: **Upregulation of mitochondrial Nox4 mediates TGF- β -induced apoptosis in cultured mouse podocytes.** *Am J Physiol Renal Physiol.* 2014; 306(2): F155–67.
[PubMed Abstract](#) | [Publisher Full Text](#)
238. Feng X, Lu TC, Chuang PY, *et al.*: **Reduction of Stat3 activity attenuates HIV-induced kidney injury.** *J Am Soc Nephrol.* 2009; 20(10): 2138–46.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
239. Dai Y, Gu L, Yuan W, *et al.*: **Podocyte-specific deletion of signal transducer and activator of transcription 3 attenuates nephrotoxic serum-induced glomerulonephritis.** *Kidney Int.* 2013; 84(5): 950–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
240. Akhezzr M, Dryer SE: **STAT3 regulates steady-state expression of synaptopodin in cultured mouse podocytes.** *Mol Pharmacol.* 2015; 87(2): 231–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
241. Chugh SS: **Transcriptional regulation of podocyte disease.** *Transl Res.* 2007; 149(5): 237–42.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
242. Zhang SY, Kamal M, Dahan K, *et al.*: **c-mip impairs podocyte proximal signaling and induces heavy proteinuria.** *Sci Signal.* 2010; 3(122): ra39.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
243. Sendeyo K, Audard V, Zhang SY, *et al.*: **Upregulation of c-mip is closely related to podocyte dysfunction in membranous nephropathy.** *Kidney Int.* 2013; 83(3): 414–25.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
244. Takemoto M, He L, Norlin J, *et al.*: **Large-scale identification of genes implicated in kidney glomerulus development and function.** *EMBO J.* 2006; 25(5): 1160–74.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
245. Brukamp K, Jim B, Moeller MJ, *et al.*: **Hypoxia and podocyte-specific *Vhl* deletion confer risk of glomerular disease.** *Am J Physiol Renal Physiol.* 2007; 293(4): F1397–407.
[PubMed Abstract](#) | [Publisher Full Text](#)
246. Steenhard BM, Isom K, Stroganova L, *et al.*: **Deletion of von Hippel-Lindau in glomerular podocytes results in glomerular basement membrane thickening, ectopic subepithelial deposition of collagen $\{\alpha\}1\{\alpha\}2\{\alpha\}1\{\text{IV}\}$, expression of neuroglobin, and proteinuria.** *Am J Pathol.* 2010; 177(1): 84–96.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
247. **F** Ding M, Cui S, Li C, *et al.*: **Loss of the tumor suppressor *Vhl* leads to upregulation of *Cxcr4* and rapidly progressive glomerulonephritis in mice.** *Nat Med.* 2006; 12(9): 1081–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
248. **F** Mallipattu SK, Horne SJ, D'Agati V, *et al.*: **Krüppel-like factor 6 regulates mitochondrial function in the kidney.** *J Clin Invest.* 2015; 125(3): 1347–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
249. Chen H, Lun Y, Ovchinnikov D, *et al.*: **Limb and kidney defects in *Lmx1b* mutant mice suggest an involvement of *LMX1B* in human nail patella syndrome.** *Nat Genet.* 1998; 19(1): 51–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
250. Morello R, Zhou G, Dreyer SD, *et al.*: **Regulation of glomerular basement membrane collagen expression by *LMX1B* contributes to renal disease in nail patella syndrome.** *Nat Genet.* 2001; 27(2): 205–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
251. Miner JH, Morello R, Andrews KL, *et al.*: **Transcriptional induction of slit diaphragm genes by *Lmx1b* is required in podocyte differentiation.** *J Clin Invest.* 2002; 109(8): 1065–72.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
252. Rohr C, Prestel J, Heidet L, *et al.*: **The LIM-homeodomain transcription factor *Lmx1b* plays a crucial role in podocytes.** *J Clin Invest.* 2002; 109(8): 1073–82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
253. Suleiman H, Heudobler D, Raschta AS, *et al.*: **The podocyte-specific inactivation of *Lmx1b*, *Ldb1* and *E2a* yields new insight into a transcriptional network in podocytes.** *Dev Biol.* 2007; 304(2): 701–12.
[PubMed Abstract](#) | [Publisher Full Text](#)
254. Burghardt T, Kastner J, Suleiman H, *et al.*: ***LMX1B* is essential for the maintenance of differentiated podocytes in adult kidneys.** *J Am Soc Nephrol.* 2013; 24(11): 1830–48.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
255. Sadl V, Jin F, Yu J, *et al.*: **The mouse *Kreisler* (*Krml1/MafB*) segmentation gene is required for differentiation of glomerular visceral epithelial cells.** *Dev Biol.* 2002; 249(1): 16–29.
[PubMed Abstract](#) | [Publisher Full Text](#)
256. Moriguchi T, Hamada M, Morito N, *et al.*: ***MafB* is essential for renal development and *F4/80* expression in macrophages.** *Mol Cell Biol.* 2006; 26(15): 5715–27.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
257. **F** Wang Y, Jarad G, Tripathi P, *et al.*: **Activation of NFAT signaling in podocytes causes glomerulosclerosis.** *J Am Soc Nephrol.* 2010; 21(10): 1657–66.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
258. Nijenhuis T, Sloan AJ, Hoenderop JG, *et al.*: **Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway.** *Am J Pathol.* 2011; 179(4): 1719–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
259. Barua M, Stellacci E, Stella L, *et al.*: **Mutations in *PAX2* associate with adult-onset FSGS.** *J Am Soc Nephrol.* 2014; 25(9): 1942–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
260. Cui S, Li C, Ema M, *et al.*: **Rapid isolation of glomeruli coupled with gene expression profiling identifies downstream targets in *Pod1* knockout mice.** *J Am Soc Nephrol.* 2005; 16(11): 3247–55.
[PubMed Abstract](#) | [Publisher Full Text](#)
261. Zhou Y, Kong X, Zhao P, *et al.*: **Peroxisome proliferator-activated receptor- α is renoprotective in doxorubicin-induced glomerular injury.** *Kidney Int.* 2011; 79(12): 1302–11.
[PubMed Abstract](#) | [Publisher Full Text](#)
262. Matsui I, Ito T, Kurihara H, *et al.*: ***Snail*, a transcriptional regulator, represses nephrin expression in glomerular epithelial cells of nephrotic rats.** *Lab Invest.* 2007; 87(3): 273–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
263. Buelli S, Rosanò L, Gagliardini E, *et al.*: **β -arrestin-1 drives endothelin-1-mediated podocyte activation and sustains renal injury.** *J Am Soc Nephrol.* 2014; 25(3): 523–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
264. Ito S, Ikeda M, Takata A, *et al.*: **Nephrotic syndrome and end-stage renal disease with *WT1* mutation detected at 3 years.** *Pediatr Nephrol.* 1999; 13(9): 790–1.
[PubMed Abstract](#) | [Publisher Full Text](#)
265. Guo JK, Menke AL, Gubler MC, *et al.*: ***WT1* is a key regulator of podocyte function: reduced expression levels cause crescentic glomerulonephritis and mesangial sclerosis.** *Hum Mol Genet.* 2002; 11(6): 651–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
266. Patek CE, Fleming S, Miles CG, *et al.*: **Murine Denys-Drash syndrome: evidence of podocyte de-differentiation and systemic mediation of glomerulosclerosis.** *Hum Mol Genet.* 2003; 12(18): 2379–94.
[PubMed Abstract](#) | [Publisher Full Text](#)
267. Chau YY, Brownstein D, Mjoseng H, *et al.*: **Acute multiple organ failure in adult mice deleted for the developmental regulator *Wt1*.** *PLoS Genet.* 2011; 7(12): e1002404.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
268. Hall G, Gbadegesin RA, Lavin P, *et al.*: **A novel missense mutation of Wilms' Tumor 1 causes autosomal dominant FSGS.** *J Am Soc Nephrol.* 2015; 26(4): 831–43.
[PubMed Abstract](#) | [Publisher Full Text](#)
269. Kumar PA, Kotlyarevska K, Dejkharon P, *et al.*: **Growth hormone (GH)-dependent expression of a natural antisense transcript induces zinc finger E-box-binding homeobox 2 (*ZEB2*) in the glomerular podocyte: a novel action of gh with implications for the pathogenesis of diabetic nephropathy.** *J Biol Chem.* 2010; 285(41): 31148–56.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
270. Liu G, Clement LC, Kanwar YS, *et al.*: **ZHX proteins regulate podocyte gene expression during the development of nephrotic syndrome.** *J Biol Chem.* 2006; 281(51): 39681–92.
[PubMed Abstract](#) | [Publisher Full Text](#)
271. Lin Y, Rao J, Zha XL, *et al.*: **Angiopoietin-like 3 induces podocyte F-actin rearrangement through integrin $\alpha(V)\beta3$ /FAK/PI3K pathway-mediated Rac1 activation.** *Biomed Res Int.* 2013; 2013: 135608.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

272. **F** Fiorina P, Vergani A, Bassi R, *et al.*: **Role of podocyte B7-1 in diabetic nephropathy.** *J Am Soc Nephrol.* 2014; 25(7): 1415–29.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
273. Iglesias-de la Cruz MC, Ziyadeh FN, Isono M, *et al.*: **Effects of high glucose and TGF-beta1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes.** *Kidney Int.* 2002; 62(3): 901–13.
[PubMed Abstract](#) | [Publisher Full Text](#)
274. Han SY, Kang YS, Jee YH, *et al.*: **High glucose and angiotensin II increase beta1 integrin and integrin-linked kinase synthesis in cultured mouse podocytes.** *Cell Tissue Res.* 2006; 323(2): 321–32.
[PubMed Abstract](#) | [Publisher Full Text](#)
275. Ha TS: **High glucose and advanced glycosylated end-products affect the expression of alpha-actinin-4 in glomerular epithelial cells.** *Nephrology (Carlton).* 2006; 11(5): 435–41.
[PubMed Abstract](#) | [Publisher Full Text](#)
276. Kim NH, Rincon-Choles H, Bhandari B, *et al.*: **Redox dependence of glomerular epithelial cell hypertrophy in response to glucose.** *Am J Physiol Renal Physiol.* 2006; 290(3): F741–51.
[PubMed Abstract](#) | [Publisher Full Text](#)
277. De Petris L, Hruska KA, Chiechio S, *et al.*: **Bone morphogenetic protein-7 delays podocyte injury due to high glucose.** *Nephrol Dial Transplant.* 2007; 22(12): 3442–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
278. **F** Wei C, El Hindi S, Li J, *et al.*: **Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.** *Nat Med.* 2011; 17(8): 952–60.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
279. Koukouritaki SB, Vardaki EA, Papakonstanti EA, *et al.*: **TNF-alpha induces actin cytoskeleton reorganization in glomerular epithelial cells involving tyrosine phosphorylation of paxillin and focal adhesion kinase.** *Mol Med.* 1999; 5(6): 382–92.
[PubMed Abstract](#) | [Free Full Text](#)
280. Saito Y, Okamura M, Nakajima S, *et al.*: **Suppression of nephrin expression by TNF-alpha via interfering with the cAMP-retinoic acid receptor pathway.** *Am J Physiol Renal Physiol.* 2010; 298(6): F1436–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
281. Bitzan M, Babayeva S, Vasudevan A, *et al.*: **TNF α pathway blockade ameliorates toxic effects of FSGS plasma on podocyte cytoskeleton and β 3 integrin activation.** *Pediatr Nephrol.* 2012; 27(12): 2217–26.
[PubMed Abstract](#) | [Publisher Full Text](#)
282. **F** Tian D, Jacobo SM, Billings D, *et al.*: **Antagonistic regulation of actin dynamics and cell motility by TRPC5 and TRPC6 channels.** *Sci Signal.* 2010; 3(145): ra77.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
283. Yoshida S, Nagase M, Shibata S, *et al.*: **Podocyte injury induced by albumin overload *in vivo* and *in vitro*: involvement of TGF-beta and p38 MAPK.** *Nephron Exp Nephrol.* 2008; 108(3): e57–68.
[PubMed Abstract](#) | [Publisher Full Text](#)
284. He F, Chen S, Wang H, *et al.*: **Regulation of CD2-associated protein influences podocyte endoplasmic reticulum stress-mediated apoptosis induced by albumin overload.** *Gene.* 2011; 484(1–2): 18–25.
[PubMed Abstract](#) | [Publisher Full Text](#)
285. **F** Okamura K, Dummer P, Kopp J, *et al.*: **Endocytosis of albumin by podocytes elicits an inflammatory response and induces apoptotic cell death.** *PLoS One.* 2013; 8(1): e54817.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
286. Shibata S, Nagase M, Yoshida S, *et al.*: **Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1.** *Hypertension.* 2007; 49(2): 355–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
287. Zhu C, Huang S, Yuan Y, *et al.*: **Mitochondrial dysfunction mediates aldosterone-induced podocyte damage: a therapeutic target of PPAR γ .** *Am J Pathol.* 2011; 178(5): 2020–31.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
288. **F** Su M, Dhooon AR, Yuan Y, *et al.*: **Mitochondrial dysfunction is an early event in aldosterone-induced podocyte injury.** *Am J Physiol Renal Physiol.* 2013; 305(4): F520–31.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
289. **F** Dai R, Lin Y, Liu H, *et al.*: **A vital role for Angptl3 in the PAN-induced podocyte loss by affecting detachment and apoptosis *in vitro*.** *BMC Nephrol.* 2015; 16: 38.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
290. **F** Ding G, Reddy K, Kapasi AA, *et al.*: **Angiotensin II induces apoptosis in rat glomerular epithelial cells.** *Am J Physiol Renal Physiol.* 2002; 283(1): F173–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
291. Jia J, Ding G, Zhu J, *et al.*: **Angiotensin II infusion induces nephrin expression changes and podocyte apoptosis.** *Am J Nephrol.* 2008; 28(3): 500–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
292. Zhang H, Ding J, Fan Q, *et al.*: **TRPC6 up-regulation in Ang II-induced podocyte apoptosis might result from ERK activation and NF-kappaB translocation.** *Exp Biol Med (Maywood).* 2009; 234(9): 1029–36.
[PubMed Abstract](#) | [Publisher Full Text](#)
293. Ren Z, Liang W, Chen C, *et al.*: **Angiotensin II induces nephrin dephosphorylation and podocyte injury: role of caveolin-1.** *Cell Signal.* 2012; 24(2): 443–50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
294. Sanchez-Niño MD, Sanz AB, Sanchez-Lopez E, *et al.*: **HSP27/HSPB1 as an adaptive podocyte antiapoptotic protein activated by high glucose and angiotensin II.** *Lab Invest.* 2012; 92(1): 32–45.
[PubMed Abstract](#) | [Publisher Full Text](#)
295. **F** Sieber J, Lindenmeyer MT, Kampe K, *et al.*: **Regulation of podocyte survival and endoplasmic reticulum stress by fatty acids.** *Am J Physiol Renal Physiol.* 2010; 299(4): F821–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
296. Sieber J, Weins A, Kampe K, *et al.*: **Susceptibility of podocytes to palmitic acid is regulated by stearoyl-CoA desaturases 1 and 2.** *Am J Pathol.* 2013; 183(3): 735–44.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
297. Kampe K, Sieber J, Orellana JM, *et al.*: **Susceptibility of podocytes to palmitic acid is regulated by fatty acid oxidation and inversely depends on acetyl-CoA carboxylases 1 and 2.** *Am J Physiol Renal Physiol.* 2014; 306(4): F401–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
298. **F** Susztak K, Raff AC, Schiffer M, *et al.*: **Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy.** *Diabetes.* 2006; 55(1): 225–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
299. **F** Peters I, Tossidou I, Achenbach J, *et al.*: **IGF-binding protein-3 modulates TGF-beta/BMP-signaling in glomerular podocytes.** *J Am Soc Nephrol.* 2006; 17(6): 1644–56.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
300. **F** Bussolati B, Deregibus MC, Fonsato V, *et al.*: **Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/AKT-signaling pathway.** *J Am Soc Nephrol.* 2005; 16(7): 1936–47.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
301. Schiffer M, Mundel P, Shaw AS, *et al.*: **A novel role for the adaptor molecule CD2-associated protein in transforming growth factor-beta-induced apoptosis.** *J Biol Chem.* 2004; 279(35): 37004–12.
[PubMed Abstract](#) | [Publisher Full Text](#)
302. **F** Wada T, Pippin JW, Terada Y, *et al.*: **The cyclin-dependent kinase inhibitor p21 is required for TGF-beta1-induced podocyte apoptosis.** *Kidney Int.* 2005; 68(4): 1618–29.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
303. Wu DT, Bitzer M, Ju W, *et al.*: **TGF-beta concentration specifies differential signaling profiles of growth arrest/differentiation and apoptosis in podocytes.** *J Am Soc Nephrol.* 2005; 16(11): 3211–21.
[PubMed Abstract](#) | [Publisher Full Text](#)
304. Jung KY, Chen K, Kretzler M, *et al.*: **TGF-beta1 regulates the PINCH-1-integrin-linked kinase-alpha-parvin complex in glomerular cells.** *J Am Soc Nephrol.* 2007; 18(1): 66–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
305. Yadav A, Vallabu S, Arora S, *et al.*: **ANG II promotes autophagy in podocytes.** *Am J Physiol Cell Physiol.* 2010; 299(2): C488–96.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
306. Ma T, Zhu J, Chen X, *et al.*: **High glucose induces autophagy in podocytes.** *Exp Cell Res.* 2013; 319(6): 779–89.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
307. Liu Y: **New insights into epithelial-mesenchymal transition in kidney fibrosis.** *J Am Soc Nephrol.* 2010; 21(2): 212–22.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
308. Li Y, Kang YS, Dai C, *et al.*: **Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria.** *Am J Pathol.* 2008; 172(2): 299–308.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
309. Husain M, Gusella GL, Klotman ME, *et al.*: **HIV-1 Nef induces proliferation and anchorage-independent growth in podocytes.** *J Am Soc Nephrol.* 2002; 13(7): 1806–15.
[PubMed Abstract](#) | [Publisher Full Text](#)
310. Sunamoto M, Husain M, He JC, *et al.*: **Critical role for Nef in HIV-1-induced podocyte dedifferentiation.** *Kidney Int.* 2003; 64(5): 1695–701.
[PubMed Abstract](#) | [Publisher Full Text](#)
311. Bruggeman LA, Drawz PE, Kahoud N, *et al.*: **TNFR2 interposes the proliferative and NF-kB-mediated inflammatory response by podocytes to TNF- α .** *Lab Invest.* 2011; 91(3): 413–25.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
312. **F** Clement LC, Macé C, Avila-Casado C, *et al.*: **Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome.** *Nat Med.* 2014; 20(1): 37–46.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
313. **F** Isermann B, Vinnikov IA, Madhusudhan T, *et al.*: **Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis.** *Nat Med.* 2007; 13(11): 1349–58.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)

314. Madhusudhan T, Wang H, Straub BK, *et al.*: **Cytoprotective signaling by activated protein C requires protease-activated receptor-3 in podocytes.** *Blood*. 2012; **119**(3): 874–83.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
315. Mitu GM, Wang S, Hirschberg R: **BMP7 is a podocyte survival factor and rescues podocytes from diabetic injury.** *Am J Physiol Renal Physiol*. 2007; **293**(5): F1641–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
316. Foster RR, Hole R, Anderson K, *et al.*: **Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes.** *Am J Physiol Renal Physiol*. 2003; **284**(6): F1263–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
317. Foster RR, Saleem MA, Mathieson PW, *et al.*: **Vascular endothelial growth factor and nephrin interact and reduce apoptosis in human podocytes.** *Am J Physiol Renal Physiol*. 2005; **288**(1): F48–57.
[PubMed Abstract](#) | [Publisher Full Text](#)
318. Müller-Deile J, Worthmann K, Saleem M, *et al.*: **The balance of autocrine VEGF-A and VEGF-C determines podocyte survival.** *Am J Physiol Renal Physiol*. 2009; **297**(6): F1656–67.
[PubMed Abstract](#) | [Publisher Full Text](#)
319. Foster RR, Satchell SC, Seckley J, *et al.*: **VEGF-C promotes survival in podocytes.** *Am J Physiol Renal Physiol*. 2006; **291**(1): F196–207.
[PubMed Abstract](#) | [Publisher Full Text](#)
320. Barisoni L, Schnaper HW, Kopp JB: **A proposed taxonomy for the podocytopathies: a reassessment of the primary nephrotic diseases.** *Clin J Am Soc Nephrol*. 2007; **2**(3): 529–42.
[PubMed Abstract](#) | [Publisher Full Text](#)
321. Chiang C, Inagi R: **Glomerular diseases: genetic causes and future therapeutics.** *Nat Rev Nephrol*. 2010; **6**(9): 539–54.
[PubMed Abstract](#) | [Publisher Full Text](#)
322. Smeets B, Moeller MJ: **Parietal epithelial cells and podocytes in glomerular diseases.** *Semin Nephrol*. 2012; **32**(4): 357–67.
[PubMed Abstract](#) | [Publisher Full Text](#)
323. Pollak MR: **The genetic basis of FSGS and steroid-resistant nephrosis.** *Semin Nephrol*. 2003; **23**(2): 141–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
324. Löwik MM, Groenen PJ, Levchenko EN, *et al.*: **Molecular genetic analysis of podocyte genes in focal segmental glomerulosclerosis—a review.** *Eur J Pediatr*. 2009; **168**(11): 1291–304.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
325. Kuppe C, Gröne HJ, Ostendorf T, *et al.*: **Common histological patterns in glomerular epithelial cells in secondary focal segmental glomerulosclerosis.** *Kidney Int*. 2015; **88**(5): 990–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
326. Wiggins RC: **The spectrum of podocytopathies: a unifying view of glomerular diseases.** *Kidney Int*. 2007; **71**(12): 1205–14.
[PubMed Abstract](#) | [Publisher Full Text](#)
327. Fukuda A, Chowdhury MA, Venkatarreddy MP, *et al.*: **Growth-dependent podocyte failure causes glomerulosclerosis.** *J Am Soc Nephrol*. 2012; **23**(8): 1351–63.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
328. Kriz W, Le Hir M: **Pathways to nephron loss starting from glomerular diseases—insights from animal models.** *Kidney Int*. 2005; **67**(2): 404–19.
[PubMed Abstract](#) | [Publisher Full Text](#)
329. Savin VJ, Sharma R, Sharma M, *et al.*: **Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis.** *N Engl J Med*. 1996; **334**(14): 878–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
330. McCarthy ET, Sharma M, Savin VJ: **Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis.** *Clin J Am Soc Nephrol*. 2010; **5**(11): 2115–21.
[PubMed Abstract](#) | [Publisher Full Text](#)
331. Bose B, Cattran D: **Glomerular diseases: FSGS.** *Clin J Am Soc Nephrol*. 2014; **9**(3): 626–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
332. Hayek SS, Sever S, Ko YA, *et al.*: **Soluble Urokinase Receptor and Chronic Kidney Disease.** *N Engl J Med*. 2015; **373**(20): 1916–25.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
333. Regele HM, Filipovic E, Langer B, *et al.*: **Glomerular expression of dystroglycans is reduced in minimal change nephrosis but not in focal segmental glomerulosclerosis.** *J Am Soc Nephrol*. 2000; **11**(3): 403–12.
[PubMed Abstract](#)
334. Chugh SS, Clement LC, Macé C: **New insights into human minimal change disease: lessons from animal models.** *Am J Kidney Dis*. 2012; **59**(2): 284–92.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
335. Yang Y, Gubler M, Beauvils H: **Dysregulation of podocyte phenotype in idiopathic collapsing glomerulopathy and HIV-associated nephropathy.** *Nephron*. 2002; **91**(3): 416–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
336. Medapalli RK, He JC, Klotman PE: **HIV-associated nephropathy: pathogenesis.** *Curr Opin Nephrol Hypertens*. 2011; **20**(3): 306–11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
337. Laurinavicius A, Rennke HG: **Collapsing glomerulopathy—a new pattern of renal injury.** *Semin Diagn Pathol*. 2002; **19**(3): 106–15.
[PubMed Abstract](#)
338. Barri YM, Munshi NC, Sukumalchandra S, *et al.*: **Podocyte injury associated glomerulopathies induced by pamidronate.** *Kidney Int*. 2004; **65**(2): 634–41.
[PubMed Abstract](#) | [Publisher Full Text](#)
339. Alabaqumi M, Soos TJ, Barisoni L, *et al.*: **Collapsing glomerulopathy.** *J Am Soc Nephrol*. 2006; **17**(10): 2854–63.
[PubMed Abstract](#) | [Publisher Full Text](#)
340. Detwiler RK, Falk RJ, Hogan SL, *et al.*: **Collapsing glomerulopathy: a clinically and pathologically distinct variant of focal segmental glomerulosclerosis.** *Kidney Int*. 1994; **45**(5): 1416–24.
[PubMed Abstract](#) | [Publisher Full Text](#)
341. Atta MG, Gallant JE, Rahman MH, *et al.*: **Antiretroviral therapy in the treatment of HIV-associated nephropathy.** *Nephrol Dial Transplant*. 2006; **21**(10): 2809–13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
342. Gherardi D, D'Agati V, Chu TH, *et al.*: **Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202.** *J Am Soc Nephrol*. 2004; **15**(5): 1212–22.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
343. Vaughan MR, Pippin JW, Griffin SV, *et al.*: **ATRA induces podocyte differentiation and alters nephrin and podocin expression in vitro and in vivo.** *Kidney Int*. 2005; **68**(1): 133–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
344. Alabaqumi M, Barisoni L: **Current views on collapsing glomerulopathy.** *J Am Soc Nephrol*. 2008; **19**(7): 1276–81.
[PubMed Abstract](#) | [Publisher Full Text](#)
345. D'Amico G: **The commonest glomerulonephritis in the world: IgA nephropathy.** *Q J Med*. 1987; **64**(245): 709–27.
[PubMed Abstract](#)
346. Wyatt RJ, Julian BA: **IgA nephropathy.** *N Engl J Med*. 2013; **368**(25): 2402–14.
[PubMed Abstract](#) | [Publisher Full Text](#)
347. Lemley KV, Lafayette RA, Safai M, *et al.*: **Podocytopenia and disease severity in IgA nephropathy.** *Kidney Int*. 2002; **61**(4): 1475–85.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
348. Lai KN, Leung JC, Chan LY, *et al.*: **Activation of podocytes by mesangial-derived TNF-alpha: glomerulo-podocytic communication in IgA nephropathy.** *Am J Physiol Renal Physiol*. 2008; **294**(4): F945–55.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
349. Gagliardini E, Benigni A, Tomasoni S, *et al.*: **Targeted downregulation of extracellular nephrin in human IgA nephropathy.** *Am J Nephrol*. 2003; **23**(4): 277–86.
[PubMed Abstract](#) | [Publisher Full Text](#)
350. Kramer H: **Obesity and chronic kidney disease.** *Contrib Nephrol*. 2006; **151**: 1–18.
[PubMed Abstract](#) | [Publisher Full Text](#)
351. Zhou X, Hurst RD, Templeton D, *et al.*: **High glucose alters actin assembly in glomerular mesangial and epithelial cells.** *Lab Invest*. 1995; **73**(3): 372–83.
[PubMed Abstract](#)
352. Chen HM, Liu ZH, Zeng CH, *et al.*: **Podocyte lesions in patients with obesity-related glomerulopathy.** *Am J Kidney Dis*. 2006; **48**(5): 772–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
353. Griffin SV, Petermann AT, Durvasula RV, *et al.*: **Podocyte proliferation and differentiation in glomerular disease: role of cell-cycle regulatory proteins.** *Nephrol Dial Transplant*. 2003; **18**(Suppl 6): vi8–13.
[PubMed Abstract](#) | [Publisher Full Text](#)
354. Kriz W: **Podocyte is the major culprit accounting for the progression of chronic renal disease.** *Microsc Res Tech*. 2002; **57**(4): 189–95.
[PubMed Abstract](#) | [Publisher Full Text](#)
355. Kikuchi M, Wickman L, Hodgins JB, *et al.*: **Podometrics as a Potential Clinical Tool for Glomerular Disease Management.** *Semin Nephrol*. 2015; **35**(3): 245–55.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
356. Reiser J, Gupta V, Kistler AD: **Toward the development of podocyte-specific drugs.** *Kidney Int*. 2010; **77**(8): 662–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
357. Chugh SS, Macé C, Clement LC, *et al.*: **Angiotensin-like 4 based therapeutics for proteinuria and kidney disease.** *Front Pharmacol*. 2014; **5**: 23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
358. Fomoni A, Sageshima J, Wei C, *et al.*: **Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis.** *Sci Transl Med*. 2011; **3**(85): 85ra46.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)

359. Yu CC, Fornoni A, Weins A, *et al.*: **Abatacept in B7-1-positive proteinuric kidney disease.** *N Engl J Med.* 2013; **369**(25): 2416–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
360. Benigni A, Gagliardini E, Remuzzi G: **Abatacept in B7-1-positive proteinuric kidney disease.** *N Engl J Med.* 2014; **370**(13): 1261–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
361. Alachkar N, Carter-Monroe N, Reiser J: **Abatacept in B7-1-positive proteinuric kidney disease.** *N Engl J Med.* 2014; **370**(13): 1263–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
362. Salant DJ: **Podocyte Expression of B7-1/CD80: Is it a Reliable Biomarker for the Treatment of Proteinuric Kidney Diseases with Abatacept?** *J Am Soc Nephrol.* 2015; pii: ASN.2015080947.
[PubMed Abstract](#) | [Publisher Full Text](#)
363. Schiffer M, Teng B, Gu C, *et al.*: **Pharmacological targeting of actin-dependent dynamin oligomerization ameliorates chronic kidney disease in diverse animal models.** *Nat Med.* 2015; **21**(6): 601–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
364. Lee HW, Khan SQ, Faridi MH, *et al.*: **A Podocyte-Based Automated Screening Assay Identifies Protective Small Molecules.** *J Am Soc Nephrol.* 2015; **26**(11): 2741–52.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. Farhad Danesh

Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Competing Interests: No competing interests were disclosed.

2. Sumant Chugh

Division of Nephrology, University of Alabama, Birmingham, AL, USA

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research